SUPPLEMENT

FY2021 — Results booklet

FY2021PDF · 50 pages1.5 MB


-- 1 of 50 --

NORMALISED PROFIT
FROM OPERATIONS
(R million)
2017
2018
2019
2020
2021
6 069
7 747
8 266
7 048
6 494
GROSS INFLOWS
UNDER MANAGEMENT
(R million)
2017
2018
2019
2020
2021
154 833
139 062
125 554
115 061
162 043
EMBEDDED VALUE
(R million)
2017
2018
2019
2020
2021
70 834
	71 217
65 624
57 294
74 645
CORE NEW BUSINESS
API
(R million)
2017
2018
2019
2020
2021
19 173
18 329
16 137
14 660
20 951

-- 2 of 50 --

1
COMMENTARY
Strong operating performance during the pandemic and continued evolution of
the Shared-value Insurance model
The year ended 30 June 2021 was characterised by a multifaceted focus on the impact of and response to the COVID-19 pandemic,
with a notable material impact on the Group’s financial results due to elevated mortality in South Africa (SA). The Group
nonetheless delivered a robust operational performance with strong actuarial experience and growth. The growing relevance of
its Vitality Shared-value Insurance model, given the increasing importance of health, wellness and resilience, positions the Group
for growth in local and global markets.
RESILIENT OPERATING PERFORMANCE DURING COVID-19
Normalised profit from operations increased 7% to R6 494 million, notwithstanding a R2.4 billion COVID-19-related impact for
Discovery Life (R1.1 billion in prior year). New business annualised premium income (API) increased 11% to R21 325 million (core API
9%), while retention levels across the Group were strong. Normalised headline earnings (NHE) decreased by 9% to R3 406 million.
This growth was impacted by R389 million pre-tax mark-to-market foreign currency losses (R578 million pre-tax gains in prior year)
arising from a recovery of the rand during the year under review. NHE before these exchange rate effects increased 12% to
R3 711 million. Headline earnings grew more than nine-fold to R2 986 million as the long-term interest rates stabilised in SA and the
United Kingdom (UK), which resulted in materially lower economic basis changes than the prior period.
The following table demonstrates the contribution of key businesses to the growth in normalised profit from operations.
Business
Current
period in
ZAR million
% change
(Current period
vs prior period) 	Strategic observation
Discovery Health 	3 423 	7%
Continued operational excellence, growth in lives and providing
significant support to members and society
Discovery Life 	1 341 	(55%)
Significant negative COVID-19-related mortality impact but
delivering positive actuarial experience and maintaining financial
strength
Discovery Invest 	1 084 	31%
Strong earnings growth, retention and solid investment returns for
clients. New business growth impacted by lower guaranteed plan
sales
VitalityHealth 1 	953 	15%
Robust operating performance driven by continued good retention.
Careful management of delay of elective healthcare in the
COVID-19 environment
VitalityLife 	644 	337%
Strong recovery and a strengthening of underlying actuarial basis
– a successful execution of the management plan. New business
slowed with lockdowns and the focus on quality business
Profit from established
businesses 2 	7 488 	-1%
Robust growth across all established businesses, except
for Discovery Life
Discovery Insure 	250 	2%
Strong new business growth and robust underwriting performance,
with earnings impacted by lower investment yields
Vitality Group 	417 	35%
Stronger growth due to increasing integration and traction with
existing partners and accelerating roll-out to new markets and
adjacencies
Ping An Health
Insurance (PAH) 	411 	126%
Focus on profit quality and scale through distribution channels and
product diversification. Capital injection to support long-term
growth
Emerging businesses 	1 078 	46% 	Emerging business delivered particularly strong growth
New initiatives
(Excluding Discovery
Bank) 	(978) 	Lower by 7%
Lower spend combined with strong growth in new business API, up
156%
Discovery Bank 	(1 094) 	Lower by 7%
Strong high-quality client and deposit growth while deliberately
pursuing a prudent, quality-focused credit strategy
Normalised profit from
operations 	6 494 	7%
1 VitalityHealth accelerated the repayment terms of its existing reinsurance programme reducing the net premiums received in the year under
review, with a net in-period impact of £39.7 million, which results in better matching of the underlying claims experience expected from the catch-
up in claims in future years.
2 Includes SA Vitality, R43 million (prior: R7 million)

-- 3 of 50 --

2 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
RESPONDING TO COVID-19 AS
DISCOVERY LIFE’S EARNINGS
IMPACTED BY R2.4 BILLION FOR THE
REPORTING YEAR
The impact of COVID-19 has been significantly worse than
expected in SA and we estimate that the SA epidemic has
turned out to be five times more severe, on a risk-adjusted
basis, than in the UK. At the end of the previous year, Discovery
Life established a R2 billion provision (R1.1 billion impact net
of discretionary margins) for retail claims and lapses which
proved adequate for the retail business’ in-period claims, as
the strong lapse experience mitigated the elevated mortality.
Given the expected mortality claims from the run-off of the
third COVID-19 wave beyond the reporting year and expected
claims from an anticipated fourth wave, an additional
provision for the retail business was set up at the end of the
year under review.
Due to the accounting treatment applicable to the short-term
contract boundary policies of group life business, Discovery
Life could not establish a provision for future group life claims
at the end of the previous year. As a result, the high in-period
group life COVID-19-related claims caused further strain in the
reporting year. At the end of the year under review, group life
provisions have been made up to the next policy renewal date
to the extent that existing contracts are deemed to be onerous.
The combined impact on Discovery Life’s overall operating profit
from these factors was R2.4 billion for the reporting year.
Given that global and local data strongly support the safety
and efficacy of vaccination, Discovery continues to play a
leadership role in driving up national vaccination rates, through
its own employees, through its products, and working closely
with the National Department of Health on the country’s
vaccination roll out. To this end, Discovery has established nine
vaccination sites nationally, requiring approximately 1 000
employees and spent R42 million in the year under review,
with an anticipated spend of R200 million in the 2022 financial
year. For its employees, Discovery intends to move to a
mandatory vaccination policy effective 1 January 2022 given
the clear moral and social obligation, as informed by our core
purpose to make people healthier and to enhance and protect
their lives; and by our values, particularly, acting as a force for
social good; and supported by a legal obligation to protect and
safeguard all employees from all potential risks.
COMMENTARY continued
HEADLINE EARNINGS BOOSTED BY
STABILISATION OF INTEREST RATES
AND BASIC EARNINGS GAINED
FURTHER FROM CMT TRANSACTION
The strong growth in headline earnings, of 909%, was largely
due to the materially lower negative pre-tax impact of
economic assumption changes (of R519 million) in the
reporting year, versus R4 830 million in the prior year, which
are excluded from the normalised measures. In SA, the key
driver of the improvement in the reporting period was the
stabilisation of longer-term interest rates compared with the
increase experienced in the prior period. In the UK, the interest
rate hedge proved effective in a year with volatile interest rate
markets, with increased costs a function of more regular
rebalancing of the hedge and higher convexity.
Basic earnings of R3 157 million (prior period R97 million)
benefitted further from a material pre-tax unrealised gain of
R537 million from the transaction in which Cambridge Mobile
Telematics (CMT) acquired TrueMotion. This acquisition was
effected through an issuance of shares, as announced by CMT
on 16 June 2021, and Discovery’s gain was for an effective
dilution of 1.69% of the equity on a fully-diluted basis. Discovery
still owns 7.89% (on a fully-diluted basis) of the equity of the
combined organisation.
CAPITAL STRENGTH AND LIQUIDITY
A disciplined long-term capital plan remains a key focus as
Discovery continues to follow a highly structured approach to
navigating the impact of COVID-19 while ensuring that the
Group remains resilient and able to continue to fund its growth
initiatives. Each of the Group’s businesses are strongly
capitalised with capital metrics above set targets, and across
the Group there is an excess of liquid assets above minimum
regulatory capital requirements of R13.4 billion, held
predominantly within the businesses, with excess liquidity held
at the centre in SA of R2 billion. The Group’s Financial Leverage
Ratio stabilised at 25.7%3 and is comfortably within the
internally set guidance level of 28% and expected to trend
down over time.
During the period under review, the Group became aware
that due to the combined effect of the future growth prospects
of Ping An Health Insurance (PAH) and its expanding product
mix, with the evolving prudential regulatory requirements in
3 Excludes capitalised lease liabilities under IFRS16 and bank borrowings related to normal course lending and borrowing activities

-- 4 of 50 --

3
China, PAH requires additional capital of RMB2.6 billion
(approximately R6 billion). Discovery’s contribution, amounting
to approximately R1.5 billion, will be required in the near
future. Discovery is committed to its investment in PAH and its
intention is to follow its rights in this regard, aligned with
previous capital contributions it has made, and is evaluating
the optimal funding mechanism in the context of COVID-19
aligned with the discipline of the capital plan. Discovery has
previously responded to fund such growth opportunities
through equity rather than debt. If it were to raise equity
capital, Discovery would expect to follow a similar strategy as it
did in the case of the final buy-out of the FNB credit card book
in 2018, for which it raised a specific quantum, ring-fenced for
those purposes, to ensure that the discipline of capital
allocation within the capital plan remains intact. The prospects
for private healthcare and private health insurance in China
provide an excellent longterm opportunity, supported by
recent government policies emphasising the development of
healthcare and private health insurance.
DISCOVERY IS DEMONSTRATING
GROWTH ACROSS MULTIPLE
DIMENSIONS AS RELEVANCE
CONTINUES TO GROW
COVID-19 has accelerated the link between health, wellness,
resilience and mortality through the underlying behavioural
drivers of risk. As these have coalesced with the rising trends of
technology adoption and purpose-led models, Discovery has
been evolving its model to offer multi-dimensional growth
prospects; these being (1) Organic growth, (2) Geographic
growth and (3) Platform-led growth through the Vitality global
insuretech platform and the Group's institutional businesses
that sit on it.
Discovery continues to drive the execution of existing market-
specific strategies through its composite model, with the
following strategic vision established for each:
i. 	South Africa: To be the perfect composite model, number
1 in every industry, and the Bank pivoting to growth as the
composite-maker within SA
ii. 	United Kingdom: To have best-in-breed products across
businesses and operating as a fully integrated composite
business with a seamless One Vitality client journey and to
have a successful entry into motor insurance
iii. Ping An Health Insurance: To be the leading health
insurer in China with over 50 million clients
iv. Vitality Group: To be the world’s largest and most
sophisticated behavioural platform linked to financial
services
SOUTH AFRICAN COMPOSITE
Discovery Bank
FINANCIAL PERFORMANCE
Discovery Bank’s operating loss for the financial
year was R1 094 million, 7% lower than the prior
period. The Bank continued to gain traction with
362 000 clients (versus 274 000 clients in July 20204
)
and 649 000 accounts (versus 505 000 accounts in
July 20204
), expanding its existing Discovery and
non-Discovery client base and achieving 500
average daily new-to-Bank sales, in line with
the medium-term forecast. There was a steady
improvement in product mix over the year with
transaction accounts and credit cards making up
over 80% of new business. Retail deposits grew
by 167% to R8.18 billion. A deliberate decision
to pursue a prudent credit strategy resulted in
moderate advances growth of 5%4 to R3.83 billion at
30 June 2021. The quality-focused credit strategy
was evidenced by the low credit loss ratio of 4.6%,
which includes a COVID-19 overlay, and high
average client non-interest revenue (NIR) levels.
The Bank continued to focus on product innovation and
building a differentiated and sophisticated digital platform.
This included the roll out of payment platforms like Apple Pay
and Discovery Pay, an enhanced account origination journey
with unique features such as Virtual Cards; a more valuable
Discovery Miles currency; enhancements to travel benefits;
and more differentiated products in the pipeline.
There was a strong improvement in utilisation over the period.
Compared with July 2020, clients depositing their salary,
initiating debit orders and making digital payments grew
substantially, driving strong NIR levels. The shared-value
fundamentals also emerged as expected with clients on Gold
and Diamond Vitality Money status exhibiting superior banking
dynamics: 94% lower arrears rate compared with clients on
Blue Vitality Money status; four times higher spend compared
with clients on Blue status; and nine times higher average
deposits compared to the average client.
4 	Post FNB JV loan book migration.

-- 5 of 50 --

4 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
COMMENTARY continued
Discovery Health
FINANCIAL PERFORMANCE
Discovery Health’s (DH) total revenue increased
by 5% to R8 802 million for the financial year,
while normalised operating profit increased by
7% to R3 423 million demonstrating continued
operational efficiency gains. Total new business
API increased by 6% to R6 453 million (core new
business API was flat at R6 079 million), despite
the challenging economic climate. Non-medical
scheme retail products (Discovery Primary Care,
Gap Cover and Healthy Company) grew strongly
by 29%, and now account for c.193 000 lives under
DH’s administration. Total non-scheme revenue
exceeded R1 billion and now represents 13% of
total DH revenue.
Discovery Health Medical Scheme (DHMS) continued
to demonstrate excellence: new business levels
showed signs of recovery with net growth exceeding
20 000 lives for the second half of the financial year
while lapse rates declined by 7% compared with the
prior period. DHMS continued to create value for its
members and implemented a delayed contribution
increase strategy for the 2021 calendar year,
resulting in the average contribution differential
between DHMS and the next eight largest open
schemes increasing to 17.3% while maintaining its
strong financial position with an unaudited
solvency of 36.9%.
In addition to DH’s roll-out of the mass vaccination programme
to individuals and more than 50 employer groups, several
other product enhancements were launched over the financial
year, with a focus on healthcare system digitisation, quality
measurement and broadened access to care. The most notable
was the launch of the Connected Care platform which aggregates
members, providers and case managers, through a patient-
centric model, on a single digital engagement platform. DH will be
launching new product enhancements at the September 2021
launch of the 2022 products, which are focused on enhancing
DHMS’s value proposition, creating new revenue opportunities
for DH, driving deeper integration between DH and Discovery
Bank, and driving growth and retention of employer business
through an enhanced employer value proposition.
Discovery Life
FINANCIAL PERFORMANCE
Discovery Life’s normalised profit of R1.3 billion
declined 55% for the financial year due to
the material impact of higher retail and group
life mortality. New business decreased by 1% to
R2.3 billion, with slightly higher core new business
sales and lower Automatic Contribution Increases
in line with lower CPI. The embedded value
(including Invest) increased by 10% over the
period, with positive experience variances due to
exceptional retention. Discovery Life’s financial
position remains robust with solvency coverage
of 183% and strong liquidity remaining under all
modelled COVID-19 scenarios.
The total claims to be paid by Discovery Life throughout the
pandemic is estimated at R6.2 billion (gross of reinsurance),
with roughly half of this having been paid during the year
under review, providing significant support to clients. Discovery
Life 	recently 	launched 	market-first 	product 	features
recognising the material risk reduction through vaccinations,
assisting and rewarding policyholders to get vaccinated.

-- 6 of 50 --

5
Discovery Invest
FINANCIAL PERFORMANCE
Discovery Invest grew operating profit 31% to
R1 084 million, with 15% of this increase a result of
once-off items, mainly the release of COVID-19 lapse
provisions and guaranteed plan matching profits.
Total Assets under Administration increased by
18% to R117 billion. Assets under Management
increased by 21% to R76 billion, with linked funds
placed in Discovery funds increasing to 79.6%, from
78.3% in the prior year.Net inflows amounting
to R5.65 billion declined 26%, largely due to
higher outflows from anticipated guaranteed plan
maturities. New business increased 3% to R2 737
million, dampened by new guaranteed plan sales
declining 24%, in line with weaker yields being on
offer and the significant reduction of the tax asset
utilised over the last decade.
The Vitality Shared-value Insurance model has continued to
manifest with better retention than expected over the year
under review, with lapses down 13%. Strong investment
performance has been generated for clients and Discovery
Invest International’s partnership with BlackRock and Goldman
Sachs has continued to grow, with offshore sales increasing by
81%. The recently launched Discovery Megatrends Fund, in
partnership with Goldman Sachs, has seen significant traction
since April 2021. Discovery Invest looks to continue growing its
footprint through enhanced distribution capabilities, continuing
digital innovation and market-leading offerings.
Discovery Insure
FINANCIAL PERFORMANCE
Discovery Insure (DI) continued its growth
trajectory, with gross new business API increasing
by 18% over the year to R1 287 million. Gross
premium income amounted to R4 205 million,
equating to 15% growth and an estimated 7%
personal lines market share. Operating profit
increased to R250 million, 2% growth from the
prior year, impacted by lower interest rates as
well as Dynamic distance cash back of R58 million,
which have been shared with clients given lower
than normal driving behaviour.
DI’s focus on making roads safer was supplemented with
the aunch of Pothole Patrol, an initiative launched to repair
damaged roads. More than 10 000 road defects have been
repaired since May 2021 and early results show a 34%
reduction in pothole-related claims experienced in the affected
areas relative to the balance of the country.
DI continues to export its technology and IP capabilities
internationally, currently to the UK and Saudi Arabia, with
further expansion opportunities being pursued. Early signs are
positive in terms of its applicability in these markets.

-- 7 of 50 --

6 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
COMMENTARY continued
UNITED KINGDOM
FINANCIAL PERFORMANCE
The UK composite‘s normalised operating profit
increased by £61.6 million year-on-year to
£68.5 million (R1 421 million, up 945%). Earned
premiums 5 increased by 5% year-on-year to
£827.4 million (R17 160 million, up 10%), while total
lives covered increased 8% to 1.4 million.
VitalityInvest (VI) had its strongest period since inception,
continuing to build traction with wealth advisers and writing
new business flows for the financial year of £323 million (new
business API of £36 million, R741 million) which is up 68% on the
prior year. Total funds under management at 31 June 2020 was
£512 million (R10.1 billion), more than double that of 12 months
prior. The restructure of VI, which took place successfully over
the course of 2020, positions it for future growth off a
significantly reduced cost base, with losses down to £7.1 million
for the period (prior year loss £18.2 million). VI launched a new
range on Environmental, Social and Governance (ESG) focused
funds in June 2021, which have been well received.
In expanding its composite strategy, Vitality UK entered the
UK car insurance market in June with VitalityCar. VitalityCar is
a capital-light joint venture with Covéa Insurance which
will provide the regulatory capital and insurance license for
the venture. VitalityCar leverages the Shared-value Insurance
model, supporting clients to drive safely and to consider the
environmental impact of their driving behaviour.
VitalityHealth
FINANCIAL PERFORMANCE
VitalityHealth’s (VH) operating profit grew by
9% year-on-year to £46.0 million (up 15% to
R953 million). The assumed claims catch-up did not
emerge as originally anticipated, having only begun
at the end of the financial year. In light of this,
the unearned premium reserve (UPR) adjustment
recognised at 30 June 2021 was £14.2 million. The
expected catch-up in claims has been modelled
into future periods and most anticipated claims
are expected to transpire over a much longer
period providing an opportunity to accelerate
the repayment terms of its existing reinsurance
programme. This reduced the net premiums
received for the period, with a net in-period impact
of £39.7 million, which results in better matching of
the underlying claims experience expected from
the catch-up in claims in future years. New business
was resilient despite market pressures, increasing
5% year-on-year to £65.9 million (increased 10% to
R1 367 million). Earned premiums grew by 4% to
£515.6 million (R10 694 million), excluding the UPR
adjustment and the total number of lives grew
above 720 000.
In a highly competitive sales environment, sales in the
profitable individual segment grew strongly by 11%. Sales in
the SME segment were also strong at 8% growth. The direct-to-
business strategy has progressed extremely well with notable
growth in leads. Retention rates have been strong throughout
the year, being more than 13% ahead of plan, despite the
economic impact of the pandemic on clients.
Cash generation was robust over the period, with the back-
book generating £127.8 million (R2 649 million) in cash. After
new business acquisition costs and investment in developing
the business, VH generated a £56.2 million (R1 165 million)
cash surplus.
5 Based on VH and VL.

-- 8 of 50 --

7
VitalityLife
FINANCIAL PERFORMANCE
VitalityLife (VL) generated £31.0 million (R64 million)
in normalised operating profit, reversing the prior
period loss. Following the simplification launch in
September 2020, there was an increase in advisers
writing a VL policy for the first time, however
extended COVID-19 lockdown periods and a strict
focus on writing quality new business resulted in
new business reducing by 14% to £55.0 million
(-9% to R1 141 million). Exceptional retention
performance delivered strong earned premiums,
up 8% to £311.8 million (up 13% to R6 466 million),
while lives covered grew by 10% year-on-year,
exceeding 680 000. VL maintained a £5.4m
(R107 million) COVID-19 provision at 30 June 2021
considering some remaining uncertainty in the UK.
VL has implemented various initiatives over the past year to
put it in a strong position: Firstly, strengthening VL’s capital
position, lowering its cost of liquidity funding, reducing its need
for Discovery Group funding and its interest rate exposure;
secondly, right-sizing the cost base to deliver the required
profitability and return on capital, with expenses £4.5million
(6%) lower than the same period last year; finally, improving
retention, through several management actions, which
manifested as a marked reduction in lapse rates and significant
positive experience variances. The resulting effects on
operating profit were partially offset due to a strengthening of
the lapse and mortality basis for the Whole of Life book.
PING AN HEALTH INSURANCE (PAH)
FINANCIAL PERFORMANCE
PAH’s profit from operations, represented by the
Group’s share of after-tax operating profit less
the costs to support the business, grew by 126%
to R411 million, supported by positive investment
returns. Total written premium grew by 36% to
R40.6 billion (RMB17.5 billion) and new business
premium by 10% to R15.8 billion (RMB6.8 billion).
New business came off a significant surge in
demand for health insurance in the prior period
due to COVID-19, and was also affected by the
continued consolidation of the Ping An Life (PAL)
distribution force; good strides have been made
in alternative distribution channels.
The prospects for private healthcare and private health
insurance provide an excellent long-term opportunity, and
recent policies emphasise developing healthcare and private
health insurance. China is also expected to continue to grow
healthcare expenditure, due to increasing customer affluence
and an ageing population, with increased participation
from private health insurance. Recent regulatory changes in
education, technology and online pharmacies are aligned with
policy goals.
PAH focused on continued growth and increasing profitability.
The significant increase in profits was driven by prudent
operational expense management and loss ratio controls.
Overall, this has put PAH in a strong position with a margin of
5.4%, double that of competitors in the health insurance
landscape.
PAH has seen strong momentum in the long-term product,
already representing 32% of new business for the 2021 calendar
year to June, having only launched in September 2020. This
product is more capital intensive but is expected to deliver
higher embedded value margins. PAH continues to pursue
scale through diversified distribution channels. PAH is reducing
its reliance on the PAL channel and has rapidly grown business
written through other channels from 24% in the prior period to
37% in the reporting year. PAH also focused on diversifying
products and services, increasingly manifesting digitally. The
partnership with Good Doctor – the largest online healthcare
services platform – is a great opportunity to unlock the online
market. PAH has the ability to build integrated digital customer
journeys and services, thereby developing a competitive
advantage over other market players who mainly partner with
online only distribution platforms.

-- 9 of 50 --

8 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
COMMENTARY continued
Vitality Group
FINANCIAL PERFORMANCE
Vitality Group’s (VG) profit increased by 38% to
US$27.1 million (R417 million). Revenue growth
remained resilient, with fee income growing 14%
to US$82.4 million (R1.3 billion) and insurance
partners’ Vitality-integrated premiums growing by
26% to US$1.3 billion (R20 billion). The period also
saw Vitality expand to 30 markets (including SA
and the UK). Vitality membership from insurance
partners grew 33% to 2.4 million, bringing total
Vitality membership to 4.4 million.
INSURANCE PARTNERSHIPS
The year was another illustration of the continued relevance of
the Vitality Shared-value Insurance model as it transforms
partners through excellent engagement and actuarial
economics, with material latent value. Despite the onset of
COVID-19, VG launched new partnerships in Brazil, Portugal,
Mexico and Saudi Arabia, which included the first international
Vitality Drive partnership through its partnership with
Tawuniya. Vitality is expected to launch in Israel next year.
There were also two market launches from long-standing
insurance partners. AIA launched Vitality in Indonesia, and
Generali launched in Spain, bringing their total number of
markets selling Vitality-integrated insurance to nine and four,
respectively.
Sales growth in AIA markets was adversely impacted by
COVID-19 but has recovered somewhat. Sumitomo Life Vitality
met and exceeded the milestone of 500 000 polices sold and
finished the period with more than 700 000 members after
launching in 2018. Growth in North America remained strong
with increased election rates for Vitality-integrated products
resulting in Manulife Vitality (Canada) growing sales by 26%
and John Hancock Vitality (US) increasing its sales by 21%.
VITALITY USA
Revenue growth in the corporate wellness business was
undermined by COVID-19 restrictions which adversely affected
sales and reward redemption. The business nonetheless
performed well and continued to invest in innovation which will
support its sales recovery and ability to extend beyond corporate
wellness. Gateway Flex, a curated marketplace of leading health
and wellness services that Vitality members can access through
funding from their employer, went live in July 2021 offering a
range of headline partners.
GROWTH PROSPECTS AND DIVIDEND
Discovery’s business model has proven to be highly relevant
during the COVID-19 pandemic and the trends that are
consolidating are likely to accentuate this relevance going
forward. The Group is confident in its ability to capitalise on
these emerging opportunities and Discovery’s Shared-value
Insurance model positions it well to deliver continued growth
and operational resilience despite the challenging macro
environment.
Discovery Life has provided for the expected future mortality
impacts of COVID-19 given the expected retail claims. Group
life provisions have been made up to the next policy renewal
date to the extent that existing contracts are deemed to be
onerous. The effect of continued interest rate and currency
volatility in SA is expected to remain a feature of the reported
results.
The Group is considering an additional capital contribution for
PAH and Discovery intends to follow its rights in this regard,
given the excellent long-term prospects for private healthcare
and private health insurance in China.
Despite the Group’s robust capital position, due to the continued
uncertainty and potentially volatile economic environment
caused by the COVID-19 pandemic, the Discovery Board has
decided to retain its prior stated position during the pandemic
and has decided not to declare an ordinary final dividend for the
period ended 30 June 2021. The reintroduction of an ordinary
dividend will be considered on an ongoing basis.
NOTES TO ANALYSTS
– Any forecast financial information contained in this
announcement has not been reviewed or reported on by the
company’s external auditors.
– Discovery has published supplemental information on
the website. For this and other results information, go to
https://www.discovery.co.za/corporate/investor-relations and
page to Financial results and reports, Annual results 2021.
On behalf of the Board
A Gore
Group Chief Executive
ME Tucker
Chairperson
Sandton 1 September 2021

-- 10 of 50 --

9
STATEMENT OF FINANCIAL POSITION
at 30 June 2021
R million
GROUP
JUNE
2021
AUDITED
Group
June
2020
Audited
Assets
Goodwill 	4 879 	5 070
Intangible assets 	6 371 	6 381
Property and equipment 	4 188 	4 643
Assets arising from insurance contracts 	50 483 	48 042
Deferred acquisition costs 	585 	632
Assets arising from contracts with customers 	1 248 	954
Investment in equity-accounted investees 	3 459 	2 713
Deferred income tax asset 	3 948 	3 511
Financial assets
– Loans and advances to customers at amortised cost 	3 361 	1 848
– Investments at amortised cost 	5 604 	2 523
– Investments at fair value through profit or loss 	130 937 	102 714
– Derivative financial instruments at fair value through profit or loss 	249 	1 370
Insurance receivables, contract receivables and other receivables 	10 533 	11 436
Current income tax asset 	391 	182
Reinsurance contracts 	445 	400
Cash and cash equivalents 	20 013 	17 909
TOTAL ASSETS 	246 694 	210 328
Equity
Capital and reserves
Ordinary share capital and share premium 	10 151 	10 148
Perpetual preference share capital 	779 	779
Other reserves 	1 935 	3 269
Retained earnings 	33 550 	30 353
46 415 	44 549
Non-controlling interest 	4 	4
TOTAL EQUITY 	46 419 	44 553
Liabilities
Liabilities arising from insurance contracts 	100 977 	82 411
Liabilities arising from reinsurance contracts 	12 525 	12 465
Deferred income tax liability 	8 814 	8 514
Contract liabilities to customers 	776 	808
Financial liabilities
– Borrowings at amortised cost 	19 493 	19 836
– Other payables at amortised cost 	14 904 	14 233
– Deposits from customers 	8 985 	2 427
– Investment contracts at fair value through profit or loss 	32 291 	23 012
– Derivative financial instruments at fair value through profit or loss 	826 	992
Employee benefits 	315 	284
Current income tax liability 	369 	793
TOTAL LIABILITIES 	200 275 	165 775
TOTAL EQUITY AND LIABILITIES 	246 694 	210 328

-- 11 of 50 --

10 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
INCOME STATEMENT
for the year ended 30 June 2021
R million
GROUP
JUNE
2021
AUDITED
Group
June
2020
Audited
%
change
Insurance premium revenue 	55 935 	49 775
Reinsurance premiums 	(7 729) 	(6 308)
Accelerated reinsurance premiums 	(823) 	–
Net insurance premium revenue 	47 383 	43 467 	9
Fee income from administration businesses 	11 700 	11 337
Net banking fee and commission income 	480 	150
Banking fee and commission income 	633 	182
Banking fee and commission expense 	(153) 	(32)
Vitality income 	3 340 	3 875
Other income 	1 372 	1 100
Receipts arising from reinsurance contracts 	500 	–
Investment income using the effective interest rate method 	280 	379
Net bank interest and similar income 	241 	71
Bank interest and similar income using the effective interest rate 	627 	162
Bank interest and similar expense using the effective interest rate 	(386) 	(91)
Net fair value gains on financial assets at fair value through profit or loss 	11 891 	4 093
Net income 	77 187 	64 472 	20
Net claims and policyholders’ benefits 	(28 178) 	(23 246)
Claims and policyholders' benefits 	(33 972) 	(26 856)
Insurance claims recovered from reinsurers 	5 794 	3 610
Acquisition costs 	(5 033) 	(6 547)
Marketing and administration expenses 	(22 679) 	(22 118)
Amortisation of intangibles from business combinations 	(66) 	(76)
Expected credit losses 	(271) 	(181)
Recovery of expenses from reinsurers 	2 773 	2 876
Net transfer to/from assets and liabilities under insurance contracts 	(14 795) 	(13 497)
– change in assets arising from insurance contracts 	545 	2 038
– change in assets arising from reinsurance contracts 	56 	53
– change in liabilities arising from insurance contracts 	(17 941) 	(9 418)
– change in liabilities arising from reinsurance contracts 	1 755 	(462)
– economic assumption adjustments net of discretionary margins 	790 	(5 708)
Fair value adjustment to liabilities under investment contracts 	(3 634) 	(151)
Profit from operations 	5 304 	1 532 	246
Finance costs 	(1 648) 	(1 568)
Foreign exchange (losses)/gains 	(389) 	578
Impairment of goodwill 	– 	(9)
Gain on dilution and disposal of equity-accounted investments 	554 	3
Impairment of equity-accounted investments 	(149) 	–
Share of net profits from equity-accounted investments 	523 	264
Profit before tax 	4 195 	800 	424
Income tax expense 	(975) 	(624) 	(56)
Profit for the year 	3 220 	176 	1 730
Profit/(loss) attributable to:
– ordinary shareholders 	3 157 	97 	3 155
– preference shareholders 	63 	81
– non-controlling interest 	* 	(2)
3 220 	176 	1 730
Earnings per share for profit attributable to ordinary shareholders of the company
during the year (cents):
– basic 	480.7 	14.8 	3 148
– diluted 	475.4 	14.7 	3 134
* Amount is less than R500 000.

-- 12 of 50 --

11
STATEMENT OF OTHER COMPREHENSIVE INCOME
for the year ended 30 June 2021
R million
GROUP
JUNE
2021
AUDITED
Group
June
2020
Audited
%
change
Profit for the year 	3 220 	176 	1 730
Items that are or may be reclassified subsequently to profit or loss:
Currency translation differences 	(1 576) 	2 800
Cash flow hedges 	260 	(430)
– unrealised gains/(losses) 	360 	(762)
– tax on unrealised gains/losses 	(25) 	59
– (gains)/losses recycled to profit or loss 	(90) 	319
– tax on recycled gains/losses 	15 	(46)
Share of other comprehensive income from equity-accounted investments 	(312) 	293
– change in fair value of debt instruments at fair value through other
comprehensive income 	15 	3
– currency translation differences 	(327) 	290
Other comprehensive (losses)/income for the year, net of tax 	(1 628) 	2 663 	(161)
Total comprehensive income for the year 	1 592 	2 839 	(44)
Attributable to:
– ordinary shareholders 	1 529 	2 760 	(45)
– preference shareholders 	63 	81
– non-controlling interest 	* 	(2)
Total comprehensive income for the year 	1 592 	2 839 	(44)
* Amount is less than R500 000.

-- 13 of 50 --

12 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021 	13
STATEMENT OF CHANGES IN EQUITY
at 30 June 2021
Attributable to equity holders
of the Company
Attributable to equity holders
of the Company
R million
SHARE
CAPITAL
AND SHARE
PREMIUM
PREFERENCE
SHARE
CAPITAL
SHARE-
BASED
PAYMENT
RESERVE
INVESTMENT
RESERVE 1
FOREIGN
CURRENCY
TRANSLATION
RESERVE
HEDGING
RESERVE
RETAINED
EARNINGS 	TOTAL
NON-
CONTROLLING
INTEREST 	TOTAL
Year ended 30 June 2021
At beginning of the year 	10 148 	779 	195 	3 	3 675 	(604) 	30 353 	44 549 	4 	44 553
Total comprehensive income for the year 	– 	63 	– 	15 	(1 903) 	260 	3 157 	1 592 	* 	1 592
Profit for the year 	– 	63 	– 	– 	– 	– 	3 157 	3 220 	* 	3 220
Other comprehensive income 	– 	– 	– 	15 	(1 903) 	260 	– 	(1 628) 	– 	(1 628)
Transactions with owners 	3 	(63) 	294 	– 	– 	– 	40 	274 	– 	274
Issue of shares 	907 	– 	– 	– 	– 	– 	– 	907 	– 	907
Delivery of treasury shares 	3 	– 	(36) 	– 	– 	– 	40 	7 	– 	7
Increase in treasury shares 	(907) 	– 	– 	– 	– 	– 	– 	(907) 	– 	(907)
Employee share option schemes:
– Value of employee services 	– 	– 	330 	– 	– 	– 	– 	330 	– 	330
Dividends paid to preference shareholders 	– 	(63) 	– 	– 	– 	– 	– 	(63) 	– 	(63)
At end of the year 	10 151 	779 	489 	18 	1 772 	(344) 	33 550 	46 415 	4 	46 419
Year ended 30 June 2020
At beginning of the year 	10 142 	779 	41 	– 	585 	(174) 	31 669 	43 042 	* 	43 042
Total comprehensive income for the year 	– 	81 	– 	3 	3 090 	(430) 	97 	2 841 	(2) 	2 839
Profit for the year 	– 	81 	– 	– 	– 	– 	97 	178 	(2) 	176
Other comprehensive income 	– 	– 	– 	3 	3 090 	(430) 	– 	2 663 	– 	2 663
Transactions with owners 	6 	(81) 	154 	– 	– 	– 	(1 413) 	(1 334) 	6 	(1 328)
Delivery of treasury shares 	10 	– 	(10) 	– 	– 	– 	– 	– 	– 	–
Increase in treasury shares 	(4) 	– 	– 	– 	– 	– 	– 	(4) 	– 	(4)
Acquisition of subsidiaries with non-controlling interest 	– 	– 	– 	– 	– 	– 	– 	– 	6 	6
Employee share option schemes:
– Value of employee services 	– 	– 	164 	– 	– 	– 	– 	164 	– 	164
Dividends paid to preference shareholders 	– 	(81) 	– 	– 	– 	– 	– 	(81) 	– 	(81)
Dividends paid to ordinary shareholders 	– 	– 	– 	– 	– 	– 	(1 413) 	(1 413) 	– 	(1 413)
At end of the year 	10 148 	779 	195 	3 	3 675 	(604) 	30 353 	44 549 	4 	44 553
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income and those debt
instruments measured at fair value through other comprehensive income.
* Amount is less than R500 000.

-- 14 of 50 --

14 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
STATEMENT OF CASH FLOWS
for the year ended 30 June 2021
R million
GROUP
JUNE
2021
AUDITED
Group
June
2020
Audited
Cash flow from operating activities 	10 407 	8 065
Cash generated by operations 	19 485 	17 372
Purchase of investments held to back policyholder liabilities 	(54 661) 	(37 316)
Proceeds from disposal of investments held to back policyholder liabilities 	38 709 	26 218
Working capital changes 	6 972 	1 628
10 505 	7 902
Dividends received 	303 	342
Interest received 	2 513 	2 516
Interest paid 	(1 197) 	(1 406)
Taxation paid 	(1 717) 	(1 289)
Cash flow from investing activities 	(6 740) 	(3 030)
Purchase of financial assets 	(32 569) 	(26 497)
Proceeds from disposal of financial assets 	27 828 	25 532
Purchase of property and equipment 	(277) 	(290)
Proceeds from disposal of property and equipment 	21 	4
Purchase of software and other intangible assets 	(1 587) 	(1 726)
Acquisition of business net of cash 	(25) 	16
Additional investment in equity-accounted investments 	(240) 	(69)
Dividends from equity-accounted investments 	109 	–
Cash flow from financing activities 	(590) 	2 202
Purchase of treasury shares 	– 	(4)
Dividends paid to ordinary shareholders 	– 	(1 413)
Dividends paid to preference shareholders 	(63) 	(81)
Proceeds from borrowings 	1 839 	10 339
Repayment of borrowings 	(2 366) 	(6 639)
Net increase in cash and cash equivalents 	3 077 	7 237
Cash and cash equivalents at beginning of the year 	17 909 	9 403
Exchange (losses)/gains on cash and cash equivalents 	(973) 	1 269
Cash and cash equivalents at end of the year 	20 013 	17 909

-- 15 of 50 --

15
ADDITIONAL DISCLOSURE
at 30 June 2021
FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS
The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three
levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1 includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial
instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or
regulatory agency and those prices represent actual and regularly occurring market transactions on an arm's length basis.
Level 2 includes financial instruments that are valued using techniques based significantly on observable market data. Instruments
in this category are valued using:
(a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active or
(b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on
observable market data.
Level 3 includes financial instruments that are valued using valuation techniques that incorporate information other than observable
market data and where at least one input (which could have a significant effect on instruments' valuation) cannot be based on
observable market data.
R million (audited)
30 JUNE 2021
LEVEL 1 	LEVEL 2 	LEVEL 3 	TOTAL
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	40 530 	2 832 	– 	43 362
– Debt portfolios 	34 845 	1 640 	– 	36 485
– Money market portfolios 	6 451 	10 802 	– 	17 253
– Multi-asset portfolio 	33 837 	– 	– 	33 837
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	28 	– 	28
– not designated as hedging instruments 	– 	221 	– 	221
Total financial assets 	115 663 	15 523 	– 	131 186
Financial liabilities
Investment contracts at fair value through profit and loss 	– 	32 291 	– 	32 291
Derivative financial instruments at fair value
– used as cash flow hedges 	– 	461 	– 	461
– not designated as hedging instruments 	– 	365 	– 	365
Total financial liabilities 	– 	33 117 	– 	33 117
There were no transfers between level 1 and 2 during the current financial period.
During the current financial period Discovery has simplified the financial risk analysis by revising the unit of account or level at which
the financial risk has been analysed. Historically Discovery performed the analysis at a very granular level using the look–through
principle to investments in mutual funds. The updated disclosure provides information that is reliable and more relevant to users of
the financial statements and the comparative numbers have been restated accordingly.

-- 16 of 50 --

16 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
ADDITIONAL DISCLOSURE continued
at 30 June 2021
FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS continued
Specific valuation techniques used to value financial instruments in level 2
❚ 	Discovery has invested in equity linked notes offered by international banks in order to back certain unit-linked contract liabilities.
The calculation of the daily value of the equity linked investments is made by the provider of the note. Discovery has procedures
in place to ensure that these prices are correct. Aside from the daily reasonableness checks versus similar funds and movement
since the prior day’s price, the fund values are calculated with reference to a specific formula or index, disclosed to the
policyholders, which is recalculated by Discovery in order to check if the price provided by the provider is correct.
❚ 	If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange
traded financial instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques
including the use of recent arm's length market transactions, reference to the current fair value of another instrument that is
substantially the same, discounted cash flow techniques, option pricing models or other valuation techniques that provide a
reliable estimate of prices obtained in actual market transactions.
❚ 	The fair value of derivatives used for hedging purposes are calculated as follows:
(a) The fair value of call options is calculated on a Black-Scholes model.
(b) The fair value of the return swaps is calculated by discounting the future cash flows of the instruments.
(c) The fair value of interest rate swaps is calculated as the present value of the estimated future cash flows based on observable
yield curves.
R million (audited)
Restated
30 June 2020
Level 1 	Level 2 	Level 3 	Total
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	31 185 	1 563 	– 	32 748
– Debt portfolios 	28 724 	1 856 	– 	30 580
– Money market portfolios 	3 835 	9 765 	– 	13 600
– Multi-asset portfolios 	25 786 	– 	– 	25 786
Derivative financial instruments at fair value:
– used as cashflow hedges 	– 	14 	– 	14
– not designated as hedging instruments 	– 	1 356 	– 	1 356
Total financial assets 	89 530 	14 554 	– 	104 084
Financial liabilities
Investment contracts at fair value through profit and loss 	– 	23 012 	– 	23 012
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	854 	– 	854
– not designated as hedging instruments 	– 	138 	– 	138
Total financial liabilities 	– 	24 004 	– 	24 004

-- 17 of 50 --

17
ADDITIONAL DISCLOSURE continued
at 30 June 2021
EXCHANGE RATES USED IN THE PREPARATION OF THESE RESULTS
USD 	GBP 	RMB
30 June 2021
– Average 	15.42 	20.74 	2.32
– Closing 	14.28 	19.74 	2.21
30 June 2020
– Average 	15.70 	19.75 	2.21
– Closing 	17.41 	21.44 	2.46

-- 18 of 50 --

18 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021 	19
SEGMENTAL INFORMATION
for the year ended 30 June 2021
1 The inter-segment funding of R714 million reflects a notional allocation of interest earned on the negative
reserve backing policyholders' funds of guaranteed investment products and hence is transferred to
Discovery Invest.
2 This segment relates to SA Insure – Personal lines.
R million
SA
HEALTH
SA
LIFE
SA
INVEST
SA
INSURE 2
SA
VITALITY
SA
BANK
UK
HEALTH
UK
LIFE
ALL OTHER
SEGMENTS
SEGMENT
TOTAL
IFRS
REPORTING
ADJUSTMENTS3
IFRS
TOTAL
Income statement
Insurance premium revenue 	294 	13 711 	14 824 	4 091 	– 	– 	11 075 	6 466 	6 351 	56 812 	(877) 	55 935
Reinsurance premiums 	1 	(3 262) 	– 	(66) 	– 	– 	(1 839) 	(3 354) 	(86) 	(8 606) 	877 	(7 729)
Accelerated reinsurance premiums 	– 	– 	– 	– 	– 	– 	(823) 	– 	– 	(823) 	– 	(823)
Net insurance premium revenue 	295 	10 449 	14 824 	4 025 	– 	– 	8 413 	3 112 	6 265 	47 383 	– 	47 383
Fee income from administration businesses 	7 540 	– 	2 401 	16 	– 	2 	28 	– 	1 724 	11 711 	(11) 	11 700
Net banking fee and commission income 	– 	– 	– 	– 	– 	464 	– 	– 	16 	480 	– 	480
Banking fee and commission income 	– 	– 	– 	– 	– 	633 	– 	– 	– 	633 	– 	633
Banking fee and commission expense 	– 	– 	– 	– 	– 	(169) 	– 	– 	16 	(153) 	– 	(153)
Vitality income 	– 	– 	– 	– 	2 295 	21 	240 	230 	554 	3 340 	– 	3 340
Other income 	968 	3 	– 	– 	– 	312 	60 	– 	10 	1 353 	19 	1 372
Receipts arising from reinsurance contracts 	– 	500 	– 	– 	– 	– 	– 	– 	– 	500 	– 	500
Investment income earned on assets backing policyholder liabilities 	– 	10 	– 	111 	– 	– 	– 	9 	9 	139 	(139) 	–
Net bank interest and similar income 	– 	– 	– 	– 	– 	214 	– 	– 	– 	214 	27 	241
Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	– 	627 	– 	– 	– 	627 	– 	627
Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	– 	(413) 	– 	– 	– 	(413) 	27 	(386)
Finance charge on negative reserve funding 	– 	– 	– 	– 	– 	– 	– 	769 	– 	769 	(769) 	–
Inter-segment funding1 	– 	(714) 	714 	– 	– 	– 	– 	– 	– 	– 	– 	–
Net fair value gains/(losses) on financial assets at fair value through
profit or loss 	6 	637 	9 172 	14 	– 	83 	29 	(792) 	1 358 	10 507 	1 384 	11 891
Net income 	8 809 	10 885 	27 111 	4 166 	2 295 	1 096 	8 770 	3 328 	9 936 	76 396 	511 	76 907
Net claims and policyholders' benefits 	(129) 	(8 113) 	(12 252) 	(2 270) 	– 	– 	(3 894) 	(837) 	(683) 	(28 178) 	– 	(28 178)
Claims and policyholders' benefits 	(129) 	(11 949) 	(12 252) 	(2 269) 	– 	– 	(5 219) 	(1 962) 	(761) 	(34 541) 	569 	(33 972)
Insurance claims recovered from reinsurers 	– 	3 836 	– 	(1) 	– 	– 	1 325 	1 125 	78 	6 363 	(569) 	5 794
Acquisition costs 	(40) 	(1 540) 	(1 056) 	(599) 	(61) 	– 	(942) 	(1 719) 	174 	(5 783) 	750 	(5 033)
Expected credit losses 	– 	– 	– 	– 	– 	(271) 	– 	– 	– 	(271) 	– 	(271)
Marketing and administration expenses
– depreciation and amortisation 	(118) 	(7) 	(11) 	(70) 	(13) 	(246) 	(447) 	(57) 	(669) 	(1 638) 	(210) 	(1 848)
– derecognition of intangible assets and property and equipment 	(26) 	– 	– 	(6) 	– 	– 	– 	(18) 	(50) 	– 	(50)
– impairment of intangible assets and property and equipment 	(15) 	– 	– 	– 	(1) 	– 	(5) 	– 	(40) 	(61) 	– 	(61)
– other expenses 	(5 058) 	(2 027) 	(1 031) 	(937) 	(2 177) 	(1 673) 	(3 297) 	(1 831) 	(2 598) 	(20 629) 	(91) 	(20 720)
Recovery of expenses from reinsurers 	– 	– 	– 	– 	– 	– 	912 	1 861 	– 	2 773 	– 	2 773
Net transfer to/from assets and liabilities under insurance contracts
– change in assets arising from insurance contracts 	– 	3 433 	– 	– 	– 	– 	– 	(6 143) 	76 	(2 634) 	3 179 	545
– change in assets arising from reinsurance contracts 	– 	33 	– 	– 	– 	13 	10 	– 	56 	– 	56
– change in liabilities arising from insurance contracts 	– 	(206) 	(11 054) 	(47) 	– 	– 	(155) 	(17) 	(6 436) 	(17 915) 	(26) 	(17 941)
– change in liabilities arising from reinsurance contracts 	– 	(1 115) 	– 	– 	– 	– 	– 	6 049 	– 	4 934 	(3 179) 	1 755
Fair value adjustment to liabilities under investment contracts 	– 	(2) 	(623) 	– 	– 	– 	– 	– 	(255) 	(880) 	(2 754) 	(3 634)
Share of net profits from equity-accounted investments 	– 	– 	– 	13 	– 	– 	(2) 	– 	512 	523 	– 	523
Impairment of equity-accounted investment 	– 	– 	– 	– 	– 	– 	– 	– 	(149) 	(149) 	– 	(149)
Normalised profit/(loss) from operations 	3 423 	1 341 	1 084 	250 	43 	(1 094) 	953 	644 	(150) 	6 494 	(1 820) 	4 674
Economic assumption adjustments net of discretionary margins and
interest rate derivative 	– 	(411) 	– 	– 	– 	– 	– 	(108) 	– 	(519) 	1 309 	790
Economic assumption adjustments net of discretionary margins 	– 	(411) 	– 	– 	– 	– 	– 	1 201 	– 	790 	– 	790
Fair value losses on VitalityLife interest rate derivative 	– 	– 	– 	– 	– 	– 	– 	(1 309) 	– 	(1 309) 	1 309 	–
Investment income earned on shareholder investments and cash 	39 	14 	40 	– 	39 	– 	– 	10 	823 	965 	(685) 	280
Net fair value gains/(losses) on financial assets at fair value through profit
or loss 	– 	138 	(28) 	– 	– 	– 	– 	139 	(471) 	(222) 	222 	–
Restructuring costs 	– 	– 	– 	– 	– 	– 	– 	(33) 	– 	(33) 	33 	–
Gain on dilution of equity-accounted investments 	– 	– 	– 	537 	– 	– 	– 	– 	17 	554 	– 	554
Expenses related to Prudential Book transfer 	– 	– 	– 	– 	– 	– 	– 	(187) 	– 	(187) 	187 	–
Transaction costs related to VitalityLife interest rate derivatives 	– 	– 	– 	– 	– 	– 	– 	(4) 	– 	(4) 	4 	–
Covid-19 vaccination programme 	– 	– 	– 	– 	– 	– 	– 	– 	(42) 	(42) 	42 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	– 	– 	– 	– 	– 	(66) 	(66) 	– 	(66)
Market rentals related to Head Office building adjusted for finance costs
and depreciation 	– 	– 	– 	– 	– 	– 	– 	– 	(228) 	(228) 	228 	–
Finance costs 	(1) 	(26) 	– 	– 	– 	– 	(7) 	(65) 	(1 192) 	(1 291) 	(357) 	(1 648)
Intercompany finance costs 	(268) 	– 	– 	– 	– 	– 	(6) 	(236) 	(315) 	(825) 	825 	–
Foreign exchange (losses)/gains 	(6) 	3 	(25) 	– 	– 	– 	– 	– 	(361) 	(389) 	– 	(389)
Profit before tax 	3 187 	1 059 	1 071 	787 	82 	(1 094) 	940 	160 	(1 985) 	4 207 	(12) 	4 195
Income tax expense 	(894) 	(364) 	(331) 	(207) 	(24) 	334 	(149) 	363 	285 	(987) 	12 	(975)
Profit for the year 	2 293 	695 	740 	580 	58 	(760) 	791 	523 	(1 700) 	3 220 	– 	3 220
3 The segment information is presented on the same basis as reported to the Chief Executive Officers of the reportable segments. The segment total
is then adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:
– The VitalityLife results, for business written on the Prudential Assurance Company license, are reclassified to account for the contractual
arrangement as a reinsurance contract under IFRS 4.
– Unit trusts which the Group controls, in terms of IFRS 10 are consolidated into Discovery's results for IFRS purposes. The IFRS reporting
adjustments include the effects of consolidating the unit trusts into Discovery's results, effectively being the income and expenses relating to
units held by third parties.
– The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments.
– The effects of reclassifying items to align to IFRS results.

-- 19 of 50 --

20 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021 	21
SEGMENTAL INFORMATION continued
for the year ended 30 June 2020
R million SA
Health SA
Life SA
Invest SA
Insure 2
SA
Vitality SA
Bank UK
Health UK
Life All other
segments Segment
total
IFRS
reporting
adjustments3
IFRS
total
Income statement
Insurance premium revenue 	252 	12 984 	15 602 	3 544 	– 	– 	9 100 	5 705 	3 330 	50 517 	(742) 	49 775
Reinsurance premiums 	(1) 	(2 564) 	– 	(66) 	– 	– 	(1 589) 	(2 789) 	(41) 	(7 050) 	742 	(6 308)
Net insurance premium revenue 	251 	10 420 	15 602 	3 478 	– 	– 	7 511 	2 916 	3 289 	43 467 	– 	43 467
Fee income from administration businesses 	7 238 	– 	2 246 	12 	– 	137 	30 	– 	1 687 	11 350 	(13) 	11 337
Net banking fee and commission income 	– 	– 	– 	– 	– 	150 	– 	– 	– 	150 	– 	150
Banking fee and commission income 	– 	– 	– 	– 	– 	182 	– 	– 	– 	182 	– 	182
Banking fee and commission expense 	– 	– 	– 	– 	– 	(32) 	– 	– 	– 	(32) 	– 	(32)
Vitality income 	– 	– 	– 	– 	2 401 	121 	452 	212 	689 	3 875 	– 	3 875
Other income 	883 	39 	– 	– 	– 	120 	69 	– 	18 	1 129 	(29) 	1 100
Investment income earned on assets backing policyholder liabilities 	– 	13 	– 	119 	– 	1 	9 	37 	1 	180 	(180) 	–
Net bank interest and similar income 	– 	– 	– 	– 	– 	63 	– 	– 	– 	63 	8 	71
Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	– 	162 	– 	– 	– 	162 	– 	162
Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	– 	(99) 	– 	– 	– 	(99) 	8 	(91)
Finance charge on negative reserve funding 	– 	– 	– 	– 	– 	– 	– 	(838) 	– 	(838) 	838 	–
Inter-segment funding1 	– 	(762) 	762 	– 	– 	– 	– 	– 	– 	– 	– 	–
Net fair value (losses)/gains on financial assets at fair value through
profit or loss 	(20) 	867 	834 	32 	(2) 	92 	29 	768 	59 	2 659 	1 434 	4 093
Net income 	8 352 	10 577 	19 444 	3 641 	2 399 	684 	8 100 	3 095 	5 743 	62 035 	2 058 	64 093
Net claims and policyholders' benefits 	(100) 	(6 079) 	(10 542) 	(1 915) 	– 	– 	(3 623) 	(798) 	(189) 	(23 246) 	– 	(23 246)
Claims and policyholders' benefits 	(100) 	(7 926) 	(10 542) 	(1 939) 	– 	– 	(4 796) 	(1 964) 	(229) 	(27 496) 	640 	(26 856)
Insurance claims recovered from reinsurers 	– 	1 847 	– 	24 	– 	– 	1 173 	1 166 	40 	4 250 	(640) 	3 610
Acquisition costs 	(30) 	(1 566) 	(1 080) 	(479) 	(66) 	– 	(797) 	(1 814) 	123 	(5 709) 	(838) 	(6 547)
Expected credit losses 	– 	– 	– 	– 	– 	(181) 	– 	– 	– 	(181) 	– 	(181)
Marketing and administration expenses
– depreciation and amortisation 	(176) 	(7) 	(9) 	(84) 	(15) 	(236) 	(359) 	(46) 	(612) 	(1 544) 	(210) 	(1 754)
– derecognition of intangible assets and property and equipment 	(29) 	– 	– 	(74) 	(9) 	– 	– 	– 	(84) 	(196) 	– 	(196)
– impairment of intangible assets 	– 	– 	– 	– 	– 	– 	– 	– 	(63) 	(63) 	– 	(63)
– other expenses 	(4 844) 	(1 976) 	(984) 	(824) 	(2 302) 	(1 438) 	(3 297) 	(2 063) 	(2 625) 	(20 353) 	260 	(20 093)
Recovery of expenses from reinsurers 	– 	– 	– 	– 	– 	– 	826 	2 050 	– 	2 876 	– 	2 876
Net transfer to/from assets and liabilities under insurance contracts
– change in assets arising from insurance contracts 	– 	1 557 	– 	– 	– 	– 	– 	(2 788) 	29 	(1 202) 	3 240 	2 038
– change in assets arising from reinsurance contracts 	– 	27 	– 	7 	– 	– 	8 	11 	– 	53 	– 	53
– change in liabilities arising from insurance contracts 	– 	(238) 	(5 809) 	(39) 	– 	– 	(28) 	(18) 	(3 110) 	(9 242) 	(176) 	(9 418)
– change in liabilities arising from reinsurance contracts 	– 	678 	– 	– 	– 	– 	– 	2 099 	– 	2 777 	(3 239) 	(462)
Fair value adjustment to liabilities under investment contracts 	– 	(2) 	(190) 	– 	– 	– 	– 	– 	4 	(188) 	37 	(151)
Share of net profits from equity-accounted investments 	17 	– 	– 	13 	– 	– 	– 	– 	222 	252 	– 	252
Normalised profit/(loss) from operations 	3 190 	2 971 	830 	246 	7 	(1 171) 	830 	(272) 	(562) 	6 069 	1 132 	7 201
Investment income earned on shareholder investments and cash 	65 	21 	45 	10 	27 	– 	1 	12 	746 	927 	(548) 	379
Economic assumption adjustments net of discretionary margins and
interest rate derivative 	– 	(3 635) 	– 	– 	– 	– 	– 	(1 195) 	– 	(4 830) 	(878) 	(5 708)
Economic assumption adjustments net of discretionary margins 	– 	(3 635) 	– 	– 	– 	– 	– 	(2 073) 	– 	(5 708) 	– 	(5 708)
Fair value gains on VitalityLife interest rate derivative 	– 	– 	– 	– 	– 	– 	– 	878 	– 	878 	(878) 	–
Net fair value gains/(losses) on financial assets at fair value through profit
or loss 	– 	128 	4 	– 	– 	– 	– 	(120) 	263 	275 	(275) 	–
Restructuring costs 	– 	– 	– 	– 	– 	– 	– 	(100) 	– 	(100) 	100 	–
Gain on dilution of equity accounted investments 	– 	– 	– 	3 	– 	– 	– 	– 	– 	3 	– 	3
Impairment of goodwill 	– 	– 	– 	– 	– 	– 	– 	– 	(9) 	(9) 	– 	(9)
Initial expenses related to Prudential Book transfer 	– 	– 	– 	– 	– 	– 	– 	(71) 	– 	(71) 	71 	–
Transaction costs related to VitalityLife interest rate derivatives 	– 	– 	– 	– 	– 	– 	– 	(45) 	– 	(45) 	45 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	– 	– 	– 	– 	– 	(76) 	(76) 	– 	(76)
Market rentals related to Head Office building adjusted for finance costs
and depreciation 	– 	– 	– 	– 	– 	– 	– 	– 	(259) 	(259) 	259 	–
Finance costs 	(11) 	– 	– 	– 	– 	– 	(7) 	(21) 	(1 180) 	(1 219) 	(349) 	(1 568)
Intercompany finance costs 	(275) 	– 	– 	– 	– 	– 	– 	(236) 	(209) 	(720) 	720 	–
Foreign exchange gains 	15 	– 	36 	– 	– 	– 	– 	– 	527 	578 	– 	578
Profit before tax 	2 984 	(515) 	915 	259 	34 	(1 171) 	824 	(2 048) 	(759) 	523 	277 	800
Income tax expense 	(826) 	147 	(256) 	(64) 	(10) 	270 	(129) 	239 	282 	(347) 	(277) 	(624)
Profit for the year 	2 158 	(368) 	659 	195 	24 	(901) 	695 	(1 809) 	(477) 	176 	– 	176
1 The inter-segment funding of R762 million reflects a notional allocation of interest earned on the negative
reserve backing policyholders' funds of guaranteed investment products and hence is transferred to Discovery
Invest.
2 This segment relates to SA Insure – Personal lines.
3 The segment information is presented on the same basis as reported to the Chief Executive Officers of the reportable segments. The segment total
is then adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:
– The VitalityLife results, for business written on the Prudential Assurance Company license, are reclassified to account for the contractual
arrangement as a reinsurance contract under IFRS 4.
– Unit trusts which the Group controls, in terms of IFRS 10 are consolidated into Discovery's results for IFRS purposes. The IFRS reporting
adjustments include the effects of consolidating the unit trusts into Discovery's results, effectively being the income and expenses relating to
units held by third parties.
– The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments.
– The effects of reclassifying items to align to IFRS results.

-- 20 of 50 --

22 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
ADDITIONAL INFORMATION
NORMALISED PROFIT FROM OPERATIONS
The following table shows the main components of the normalised profit from operations for the year ended 30 June 2021:
R million
JUNE
2021
June
2020
%
change
Discovery Health 	3 423 	3 190 	7
Discovery Life 	1 341 	2 971 	(55)
Discovery Invest 	1 084 	830 	31
Discovery Vitality 	43 	7 	514
VitalityHealth 	953 	830 	15
VitalityLife 	644 	(272) 	337
Normalised profit from established businesses 	7 488 	7 556 	(1)
Emerging businesses 	1 078 	736 	46
– Discovery Insure (Personal lines) 	250 	246 	2
– Vitality Group including Ping An Health 	828 	490 	69
Development and other segments 	(2 072) 	(2 223) 	7
– Discovery Bank 	(1 094) 	(1 171) 	7
– Other new initiatives 	(978) 	(1 052) 	7
Normalised profit from operations1 	6 494 	6 069 	7
1 This amount can be further analysed by referring to the Normalised profit/(loss) from operations as per the Segment Total in the Segmental
information.
Emerging businesses are those businesses that have achieved sufficient scale to be profitable or profitable in the near future,
although not yet significant in cash generation for the Group and likely to require funds to support new business growth.
Development and other segments include costs of start-up businesses and expenses incurred to investigate, research and develop
new products and markets. Start-up costs include costs in relation to, amongst others, Discovery Bank, the UK investment business
VitalityInvest, a commercial offering in Discovery Insure, an Umbrella Fund offering in Discovery Invest and the Vitality1 platform
being a leading behavioural change platform enabling shared-value insurance and financial services products across the Discovery
Group. Certain unallocated head office costs are also included in this segment.
REVIEW OF GROUP RESULTS
for the year ended 30 June 2021

-- 21 of 50 --

23
ADDITIONAL INFORMATION continued
NORMALISED HEADLINE EARNINGS
Discovery’s policy on the calculation of Normalised headline earnings is set out in Accounting Policies at the end of this results
announcement.
R million
GROUP
JUNE
2021
AUDITED
Group
June
2020
Audited
%
change
Earnings per share (cents):
– basic 	480.7 	14.8 	3 148
– diluted 	475.4 	14.7 	3 134
Headline earnings per share (cents):
– basic 	454.7 	45.0 	910
– diluted 	449.7 	44.7 	906
Normalised headline earnings per share (cents):
– basic 	518.7 	570.7 	(9)
– diluted 	512.9 	566.7 	(9)
The reconciliation between earnings and headline earnings is shown below:
Net profit attributable to ordinary shareholders 	3 157 	97 	3 155
Adjusted for:
– derecognition of intangible assets and property and equipment, net of tax 	40 	149
– gain on dilution and disposal of equity-accounted investments, net of tax 	(414) 	(3)
– gain on disposal of property and equipment net of capital gains tax 	(2) 	(2)
– impairment of equity-accounted investment, net of tax 	149 	–
– impairment of goodwill 	– 	9
– impairment of intangible assets net of tax 	56 	44
– Discovery Limited's share of headline earnings adustments made by equity-accounted
investees:
– derecognition of intangible assets and property and equipment net of tax 	– 	2
Headline earnings 	2 986 	296 	909
Adjusted for:
– economic assumption adustments net of discretionary margins and interest rate
derivative, net of tax 	383 	3 584
– economic assumption adustments net of discretionary margin, net of tax 	(677) 	4 295
– fair value losses/(gains) on VitalityLife interest rate derivative, net of tax 	1 060 	(711)
– other: 	37 	(133)
– amortisation of intangibles from business combinations, net of tax 	53 	60
– deferred tax asset raised on assessed losses 	(152) 	(275)
– fair value losses/(gains) on foreign exchange contracts not designated as hedges,
net of tax 	219 	(189)
– fair value (gains)/ losses on swaption contract in VitalityLife, net of tax 	(113) 	97
– initial expenses related to Prudential Book transfer, net of tax 	– 	57
– restructuring costs, net of tax 	27 	80
– transaction costs related to VitalityLife interest rate derivative, net of tax 	3 	37
Normalised headline earnings 	3 406 	3 747 	(9)
Weighted number of shares in issue (000’s) 	656 710 	656 648
Diluted weighted number of shares (000’s) 	664 073 	661 242

-- 22 of 50 --

24 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2021
SIGNIFICANT TRANSACTIONS AFFECTING THE CURRENT RESULTS
PROVISION AND RESERVES FOR EXPECTED COVID-19 IMPACT
At 30 June 2020, Discovery had reserved R3.4 billion (R2.3 billion net of discretionary margin offset), for both future claims and lapses
as a result of the COVID-19 pandemic. This estimation reflected management’s best estimate of the impact as at 30 June 2020 and
comprised of provisions in Discovery Life and VitalityLife and unearned premium reserves in VitalityHealth. Due to the utilisation of
the available discretionary margin, some of these provisions are accounted for against the discretionary margins in accordance with
IFRS and Discovery’s accounting policy.
Although the allowance for the COVID-19 impact is an abnormal provision for future impacts, it is not excluded in the presentation
of normalised headline earnings because it is seen as part of the core operations and will impact future cashflows.
The movement in the COVID-19 provision and reserves for the year ended 30 June 2021 is as follows:
R million
JUNE
2021
At beginning of the period 	3 442
– Provisions 	2 729
– Unearned premium reserve 	713
Movements:
– Unwinding, utilisation and release of provisions 	(1 886)
– Provisions made during the period, including in respect of new business 	2 177
– Net movement in unearned premium reserve 	(433)
– Other 	(220)
At end of the period 	3 080
– Provisions 	2 800
– Unearned premium reserve 	280
ACCELERATED REINSURANCE PREMIUMS - VITALITYHEALTH
VitalityHealth uses quota share reinsurance treaties as one of the mechanisms to manage the initial acquisition cost strain and
underwriting experience risk. During the current financial year, repayments on these existing reinsurance contracts were accelerated,
reducing net premiums received for the year under review and consequently reducing repayment obligations in future years. The
strategic rationale for this is set out below.
The COVID-19 pandemic resulted in a temporary reduction in claims ratios for VitalityHealth for the year ended 30 June 2021
compared to pre-pandemic levels, as various medical treatments could not be accessed or were delayed by policyholders. It is
anticipated that these delayed treatments will result in claims ratios being substantially higher than pre-pandemic levels during the
next two financial years. This is expected as a result of a catch up of delayed treatments, combined with increased severity of
conditions due to those delays.
VitalityHealth has recognised reserves as permitted by IFRS. However, VitalityHealth as a short-term insurer, is constrained in its
ability to set aside reserves for those claims that are expected to arise in future renewal periods beyond the contract boundary.
To protect itself against the expected increased claims ratio over the next two financial years, VitalityHealth has modified certain of
its existing quota share reinsurance treaties to adjust the repayment profile. The modification resulted in VitalityHealth making
additional repayments of GBP 39.7 million (R823 million) in the current financial year, with GBP19.8 million of reduced repayments
in the financial year ending 30 June 2022 and 2023 respectively. The net impact in profit or loss over the three-year period to 30 June
2023 is nil.

-- 23 of 50 --

25
SIGNIFICANT TRANSACTIONS AFFECTING THE CURRENT RESULTS continued
VITALITYHEALTH – ACCELERATED REINSURANCE REPAYMENTS continued
The additional repayments in the current financial year have been recognised as additional reinsurance premiums. The impact of
accelerated reinsurance repayments premiums can be summarised as follows:
R million
VITALITYHEALTH
JUNE 2021
VitalityHealth
June 2020
Insurance premium revenue 	11 075 	9 100
Reinsurance premium 	(1 839) 	(1 589)
Accelerated reinsurance repayments 	(823) 	–
Net insurance premium revenue 	8 413 	7 511
Claims and policyholders’ benefits 	(5 219) 	(4 796)
Insurance claims recovered from reinsurers 	1 325 	1 173
Net claims and policyholders’ benefits 	(3 894) 	(3 623)
Net underwriting results 	4 519 	3 888
Change in liabilities arising from insurance contracts 	(155) 	(28)
Ratios
Gross claims ratio – claims and policyholders’ benefits adjusted for change in liabilities
arising from insurance contracts as a percentage of insurance premium revenue 	48.52% 	53.01%
Claims ratio – net claims and policyholders’ benefits adjusted for change in liabilities
arising from insurance contracts as a percentage of net insurance premium revenue 	48.13% 	48.61%
Claims ratio (excluding accelerated reinsurance premiums) – net claims and
policyholders’ benefits adjusted for change in liabilities arising from insurance
contracts as a percentage of net insurance premium revenue excluding accelerated
reinsurance premiums 	43.84% 	–
DERIVATIVE INSTRUMENTS – VITALITYLIFE BUSINESS
Interest rates in the United Kingdom (UK) continued to display significant volatility and have generally been on a downward trend in
prior years, which was followed by an increase in the year ended 30 June 2021. As a long-term insurance provider in the UK, VitalityLife
has significant exposure to long-term interest rate risk. The impact of changes in economic assumptions for the year ended
30 June 2021 in VitalityLife was a gain of R1 201million (2020: loss of R2 073 million).
Since October 2019, VitalityLife has implemented an interest rate risk mitigation strategy to ensure that the VitalityLife business
operates well within its pre-determined risk appetite. The mitigation strategy is a combination of interest swaps referenced to the
25-year UK swap rate and put swap options (payer options).
Due to the nature of the underlying exposures, the hedge accounting requirements of IFRS were not met. Therefore, these derivative
instruments were classified at fair value with changes recognised in profit or loss throughout the term which may result in volatility
in the reported IFRS earnings of VitalityLife. At 30 June, the following mark-to-market positions were recorded:
GBP/Rand million
JUNE 2021 	June 2020
Line item in financial statements 	GBP 	R 	GBP 	R
Statement of Financial
Position
Interest rate swap
valuation
(Financial liabilities)/ Financial assets:
Derivative – financial instruments at fair value
through profit or loss 	(11.8) 	(233) 	44.3 	950
Swaption valuation 	Financial assets:
Derivative – financial instruments at fair value
through profit or loss 	6.8 	135 	0.1 	2
Income Statement
Fair value remeasurement Net fair value (losses)/gains on financial assets
at fair value through profit or loss 	(56.4) 	(1 170) 	(38.4) 	(758)
Transaction costs 	Marketing and administration expenses 	(0.2) 	(4) 	(2.3) 	(45)

-- 24 of 50 --

26 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2021
SIGNIFICANT TRANSACTIONS AFFECTING THE CURRENT RESULTS continued
VOLATILITY IN FOREIGN EXCHANGE RATES USD 	GBP
30 June 2021
– Average 	15.42 	20.74
– Closing 	14.28 	19.74
30 June 2020
– Average 	15.70 	19.75
– Closing 	17.41 	21.44
The ZAR has shown significant volatility over the last two annual reporting periods against currencies such as USD and GBP. Discovery is
exposed to foreign exchange gains or losses primarily as result of the translation of intergroup funding provided for international businesses.
During the financial year ended 30 June 2020, there was a significant weakening of the ZAR, primarily in the second half of the
financial year. As a result of this weakening in the ZAR, Discovery had recognised R424 million foreign exchange gains, net of tax
during the financial year then ended.
For the financial year ended 30 June 2021, there was a recovery of the ZAR relative to USD and GBP. This has resulted in a foreign
exchange loss, net of tax, of R305 million for the financial year. In addition, the impact of the strengthening of ZAR against the USD has
resulted in a strain on specified Discovery Life products which is included within the economic assumptions of Discovery Life.
The significant volatility has also resulted in large foreign currency translation differences during the same observed periods on the
translation of Discovery’s foreign operations into the Group’s presentation currency of ZAR. These translation differences are recognised
in other comprehensive income as part of equity and shown as “Foreign currency translation reserve”. For the year ended 30 June 2021,
Discovery recognised currency translation losses of R 1 903 million (30 June 2020: currency translations gains of R3 090 million).
CAMBRIDGE MOBILE TELEMATICS TRANSACTION
Cambridge Mobile Telematics (“CMT”), an associate investment of Discovery and strategic partner to Discovery Insure since 2014,
finalised the acquisition of Truemotion Inc. on 16 June 2021 for USD 650 million (R10 billion). The transaction subsequently received
the required approval from the U.S. regulators. Upon the completion of the transaction, Discovery’s effective shareholding in CMT
reduced from 9.58% to 7.89% on a fully diluted basis. Discovery’s profit from the transaction was USD 38.7 million (R537 million). The
profit has been included in the ‘Gain on dilution and disposal of equity-accounted investments’ in the Group Income statement.
Discovery Insure’s director representation and strategic partnership with CMT remains in place following the transaction and
accordingly the investment continues to be an associate which, is equity-accounted.

-- 25 of 50 --

27
OTHER SIGNIFICANT ITEMS IN THESE RESULTS
BORROWINGS AT AMORTISED COST
R million 	Reference
JUNE
2021
June
2020
Borrowings from Banks and listed debt 	15 230 	15 456
– United Kingdom borrowings 	i 	3 764 	3 498
– South African borrowings 	ii 	11 466 	11 958
Lease liabilities 	4 263 	4 380
– 1 Discovery Place 	3 388 	3 370
– Other lease liabilities 	875 	1 010
Total borrowings at amortised cost 	19 493 	19 836
i. United Kingdom borrowings
Facility
amount
GBP million Variable rate 	Capital repayment and maturity date
Carrying value
GBP/Rand million
JUNE 2021 	June 2020
GBP 	R 	GBP 	R
80 	3-month Libor + 265bps1 	Instalments – 31 July 2023 	73 	1 435 	80 	1 719
34 	3-month Libor + 100bps1 	At maturity – 18 April 2022 	26 	512 	28 	602
100 	3-month Libor + 229bps1 	At maturity – 31 July 2023 	89 	1 817 	55 	1 177
188 	3 764 	163 	3 498
1 Interest payable quarterly in arrears.
Total finance cost for the UK borrowings for the year ended 30 June 2021 was GBP 4.6 million (R95 million) (30 June 2020:
GBP 0.35 million (R7 million)).
ii. South African borrowings
CREDIT RATING
The national scale long term issuer rating of Discovery was reaffirmed at A1.za. However, following the downgrade of the South
African Government’s issuer rating to Ba2 from Ba1 on 20 November 2020, Moody’s Investors Service (“Moody’s”) downgraded
Discovery Limited’s Global scale long term issuer rating to Ba3 from Ba2 on 25 November 2020. The rating was reaffirmed on
8 March 2021. Similar to the country’s outlook, the credit outlook assigned by Moody’s remains negative.

-- 26 of 50 --

28 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2021
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
BORROWINGS AT AMORTISED COST continued
DISCOVERY LIMITED
Facility
amount
R million 	Variable rate
Interest rate
per annum
(fixed)
Capital repayment and
maturity date
Carrying value
R million
JUNE
2021
June
2020
Listed DMTN4
500 	3-month Jibar + 161bps 	9.71%1,3 	At maturity – 21 November 2022 	503 	503
500 	3-month Jibar + 205bps 	6.30%1,3 	At maturity – 21 August 2023 	503 	–
200 	– 	10.46%2 	At maturity – 21 November 2024 	202 	202
800 	3-month Jibar + 191bps 	10.31%1,3 	At maturity – 21 November 2024 	804 	805
1 200 	3-month Jibar + 191bps 	9.21%1,3 	At maturity – 21 November 2024 	1 220 	1 225
700 	3-month Jibar + 180bps 	10.29%1,3 	At maturity – 21 August 2026 	703 	704
300 	3-month Jibar + 180bps 	9.40%1,3 	At maturity – 21 August 2026 	302 	303
Unlisted DMTN4,5
1 100 	– 	8.92%3 	At maturity – 10 March 2023 	1 103 	1 101
2 500 	– 	9.62%3 	At maturity – 22 February 2025 	2 519 	2 516
Other
1 000 	3-month Jibar + 245bps 	10.28%1,3 	At maturity – 02 March 2023 	999 	997
500 	3-month Jibar + 86bps 	– 	At maturity – 30 June 2022 	659 	630
9 517 	8 986
1 The interest rate has been fixed through interest rate swaps.
2 Interest is payable semi-annually in arrears.
3 Interest payable quarterly in arrears.
4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017.
5 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank syndicated loans through the issue of unlisted DMTN
notes. The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market
on an ongoing basis.
DISCOVERY CENTRAL SERVICES
Facility
amount
R million
Interest rate
per annum 	Capital repayment and maturity date
Carrying value
R million
JUNE
2021
June
2020
1 400 	10.60%1 	At maturity – 20 December 2023 	1 423 	1 430
650 	11.56%2 	Instalments – 29 October 2027 	526 	542
1 949 	1 972
1 Interest payable quarterly in arrears.
2 Instalments of interest and capital are done monthly.
DISCOVERY BANK
Facility
amount
R million 	Variable rate 	Capital repayment and maturity date
Carrying value
R million
JUNE
2021
June
2020
500 	Jibar + 125bps1 	At maturity – 19 July 20212 	– 	500
500 	Jibar + 135bps1 	At maturity – 19 July 20212 	– 	500
– 	1 000
1 Interest payable quarterly in arrears.
2 These loan facilities had a maturity date of 19 July 2021 with the ability to early settle without any penalties being incurred. The loans were settled
early on 15 February 2021.
Total finance cost for in respect of South African borrowings and related hedges for the year ended 30 June 2021 was R872 million
(2020: R976 million).

-- 27 of 50 --

29
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
ANALYSIS OF CASH AND CASH EQUIVALENTS
R million
JUNE
2021
June
2020
Unit-linked investment and insurance contracts1 	4 071 	2 502
Shareholder cash 	15 942 	15 407
Closing balance 	20 013 	17 909
1 Includes cash held within specific portfolios to match specific insurance liabilities.
The shareholder Cash and cash equivalents position at 30 June 2021, increased by R0.5 billion when compared to 30 June 2020
(2020: R8.8 billion compared to 30 June 2019). The increase can mainly be attributed to the following:
R billion
INCREASE IN
SHAREHOLDER
CASH
POSITION AT
30 JUNE
2021
Increase in
shareholder
cash
position at
30 June
2020
Translation differences 	(1.0) 	1.3
Discovery Bank 	0.2 	2.0
VitalityLife 	0.6 	4.7
Other 	0.7 	0.8
Total 	0.5 	8.8
The shareholder cash balances include collateral of R2 million (2020: R1.1 billion) held in respect of derivative contracts and
R6.2 billion (2020: R6.2 billion) in respect of the deposit back related to the level premium reinsurance treaty for business written on
Prudential Assurance Company’s license. The cash held in the insurance entities in the Group is used for the funding of new business
and to match claims and other policyholder related liabilities. This cash, together with the cash balances held by Discovery Bank,
although unencumbered, is held for specific purposes and therefore not freely available for distribution. Cash available to support
Group liquidity requirements is R1.2 billion (2020: R1.1 billion).

-- 28 of 50 --

30 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2021
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
CONSOLIDATION OF DISCOVERY UNIT TRUSTS
The Discovery Unit Trusts are consolidated into Discovery’s results for accounting purposes, which results in the recognition of the
underlying assets and liabilities of each of the funds.
Assets and liabilities of the Discovery Unit Trusts increased by R4 696 million respectively, compared to the prior financial year, with
movements in the following line items on the Group’s Statement of Financial Position:
Changes in assets
❚ 	Investments at fair value through profit or loss increased by R4 812 million.
❚ 	Cash and cash equivalents increased by R459 million.
❚ 	Insurance receivables, contract receivables and other non-financial receivables decreased by R581 million.
❚ 	Other assets increased by R6 million.
Changes in liabilities
❚ 	Investment contracts at fair value through profit or loss increased by R4 636 million.
❚ 	Other liabilities increased by R60 million.
As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for shareholders.
There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The cash flow impact of the movement in
policyholder investments for the period is included in the following line items on the Group’s Statement of cash flows:
❚ 	Purchase of investments held to back policyholder liabilities includes cash outflows of R21 762 billion.
❚ 	Proceeds from the disposal of investments held to back policyholder liabilities includes cash inflows of R19 142 billion.
DISCOVERY HEALTH MEDICAL SCHEME (DHMS)
Discovery Health administers DHMS and provides managed care services for which it charges an administration fee and a managed
healthcare fee respectively. These fees are determined on an annual basis and approved by the trustees of DHMS. The fees totalled
R6 403 million for the year ended 30 June 2021 (2020: R6 190 million). Discovery offers the members of DHMS access to the Vitality
programme.
MATERIAL TRANSACTIONS WITH RELATED PARTIES
Discovery Long Term Incentive Plan Trust
At the annual general meeting held on 28 November 2019, the shareholders approved the establishment of the Discovery Long-
Term Incentive Plan Trust (“Trust”) with the purpose, inter-alia, to subscribe, purchase and/or otherwise acquire and hold Discovery
ordinary shares from time to time for the benefit of the share-based payment plan for employees, in accordance with the
requirements of the Trust. During December 2020, 7 477 865 new shares were issued by Discovery Limited to the Trust (representing
the allocation over the past two years) at a value of R907 million, with a par value of 0.01 cents per share. While held in the Trust,
these shares are treated as treasury shares and not treated as issued, for accounting purposes.

-- 29 of 50 --

31
SHAREHOLDER INFORMATION
DIRECTORATE
Changes to the Board of Discovery Limited from 1 July 2020 to the date of this announcement are as follows:
❚ 	Mr HP Mayers, formally retired as a non-executive director effective 26 November 2020.
❚ 	Ms M Schreuder has been appointed as an independent non-executive director with effect from 19 February 2021. Ms Schreuder
has been appointed as a member of the Audit Committee, Actuarial Committee as well as the Risk and Compliance Committee,
which Ms Schreuder has taken over as Chairperson with effect from 1 April 2021. Ms Schreuder’s appointment strengthens the
independence and actuarial skills on the board and respective committees.
❚ 	Ms M Hlahla has been appointed as an independent non-executive director with effect from 15 August 2021. Ms M Hlahla will be
a member of the Audit Committee as well as the Social and Ethics Committee. Ms Hlahla's appointment strengthens the
independence and business skills on the board and the committees.
Changes in executive director responsibilities from 1 July 2020 to the date of this announcement are as follows:
❚ 	Mr HD Kallner, CEO of Discovery’s South African operations, has been appointed as the new CEO of Discovery Bank and Discovery
Bank Holdings effective 1 January 2021. Mr Kallner replaces Mr BJS Hore. Mr Kallner continues to chair the SA Executive Committee,
as the core governance forum of the SA composite.
Changes in company secretary
❚ 	Mr MJ Botha formally retired as company secretary of Discovery with effect from 30 November 2020. Mr Botha held the position
since 2001 and will be retained in an advisory capacity for a period of handover.
❚ 	As a result of the formal retirement of Mr MJ Botha, the Board announced the appointment of Ms NN Mbongo as company
secretary of Discovery with effect from 1 December 2020.
Appointment of debt officer:
❚ 	In accordance with paragraph 7.3(g) of the JSE Debt Listings Requirements, Mr DM Viljoen has been appointed as the Debt officer
with effect from 2 November 2020.
DIVIDEND AND CAPITAL
Interim dividends paid in respect of the 2021 financial year
The following interim dividends were paid during the current period:
❚ 	B preference share dividend of 354.52055 cents per share (283.61644 cents net of dividend withholding tax), paid on 15 March 2021.
❚ 	No ordinary share dividends were declared.

-- 30 of 50 --

32 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2021
SHAREHOLDER INFORMATION continued
DIVIDEND AND CAPITAL continued
Final dividend declaration in respect of the 2021 financial year
B PREFERENCE SHARE CASH DIVIDEND DECLARATION:
On 26 August 2021, the directors declared a final gross cash dividend of 347.12329 cents (277.69863 cents net of dividend withholding
tax) per B preference share for the period 1 January 2021 to 30 June 2021, payable from the income reserves of the Company.
A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt.
The issued preference share capital at the declaration date is 8 million B preference shares.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Monday, 20 September 2021
Shares commence trading "ex" dividend 	Tuesday, 21 September 2021
Record date 	Thursday, 23 September 2021
Payment date 	Monday, 27 September 2021
B Preference share certificates may not be dematerialised or rematerialised between Tuesday, 21 September 2021 and Thursday,
23 September 2021, both days inclusive.
ORDINARY SHARE CASH DIVIDEND DECLARATION:
Due to the uncertain and potentially volatile economic environment caused by the COVID-19 pandemic, Discovery will not be
recommending the payment of final ordinary dividends. The reintroduction of dividends will be considered when appropriate.
CAPITAL
For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies the minimum
amount and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum
required capital must be maintained at all times throughout the period.
With effect from 1 July 2018, the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential Standards were implemented
in South Africa. Discovery Life and Discovery Insure are regulated under the Insurance Act, while Vitality Health and Vitality Life are
regulated under the European Solvency II regulatory regime, which was implemented from 1 January 2016.
The table below summarises the capital requirements on the statutory basis, across the Group subsidiaries, and the actual solvency
capital held in relation to this requirement.
STATUTORY CAPITAL
REQUIREMENTS
JUNE 2021
COVER
Statutory capital
requirements
June 2020
Cover
Discovery Life 	R17 647 million 	1.8 times 	R14 835 million 	1.8 times
Discovery Insure 	R1 079 million 	1.8 times 	R885 million 	1.8 times
Vitality Health 	GBP 105.6 million (R2 084 million) 	1.6 times 	GBP 102.3 million (R2 194 million) 	1.7 times
VitalityLife Limited 	GBP 225.5 million (R4 451 million) 	2.4 times 	GBP 228.3 million (R4 896 million) 	2.0 times
A disciplined long-term capital plan remains a key focus as Discovery continues to follow a highly structured approach to navigating the
impacts of COVID-19 whilst ensuring that the Group remains resilient and able to continue to fund its growth initiatives. Each of the
Group’s businesses are strongly capitalised with capital metrics above set targets, with an excess of liquid assets above minimum regulatory
capital requirements of R13.4 billion across the Group and excess liquidity held at the centre of R2 billion in SA. The Group’s Financial
Leverage Ratio stabilised at 25.7% and is well within the internally set guidance level of 28% and expected to trend down over time.
During the period under review, the Group became aware that due to the combined effect of the future growth prospects of PAH
and its expanding product mix with the evolving Chinese prudential regulatory requirements, PAH requires additional capital of
RMB2.6 billion (approximately R6 billion), of which Discovery’s share is approximately R1.5 billion. Refer to the Commentary section
‘Capital Strength and liquidity’.

-- 31 of 50 --

33
ACCOUNTING POLICIES
NEW ACCOUNTING STANDARDS
Interest Rate Benchmark Reforms
A fundamental reform of major interest rate benchmarks is being undertaken globally, including the replacement of some interbank
offered rates (IBORs) with alternative nearly risk-free rates (referred to as ’IBOR reform’). The Group has exposures to IBORs on its
financial instruments which has been or will be replaced or reformed as part of these market-wide initiatives, such as Libor and Jibar.
There is uncertainty over the timing and the methods of transition in some jurisdictions that the Group operates in, such as South
Africa. The United Kingdom has seen a change from the GBP Libor to the Reformed Sterling Overnight Index Average (SONIA).
The International Accounting Standards Board (IASB) has undertaken a two-phase project to consider potential reliefs from the
effect of IBOR reforms. The project was concluded, and the amendments and relief are mandatorily effective from 1 July 2021 for
Discovery. However, Discovery has elected to early adopt the amendments to cater for changes in specified UK transactions in which
the contractual rate has already been changed.
❚ 	For change in contractual cash flows (i.e., GBP Libor to SONIA), the reliefs have the effect that the changes that are necessary as
a direct consequence of IBOR reform and are economically equivalent, will not result in an immediate gain or loss in profit or loss.
❚ 	The hedge accounting reliefs will allow most hedge relationships that are directly affected by IBOR reform to continue, with
additional consideration for ineffectiveness.
The Group anticipates that IBOR reform will impact some of its Jibar risk management and hedge accounting relationships in the
longer term. The South African Reserve Bank is still in the early stages of the replacement project. The Group does not have Libor
hedge accounting relationships.
NORMALISED HEADLINE EARNINGS
Discovery assesses its performance using Normalised Headline Earnings, an alternative non-IFRS profit measure, alongside its IFRS
based reported profit. Management considers that Normalised Headline Earnings Per Share (NHEPS) is an appropriate alternative
performance measure to enhance the comparability and understanding of the financial performance of the Group.
Non-IFRS measures are not uniformly defined or used by all entities and may not be comparable with similarly labelled measures
and disclosures provided by other entities.
Discovery calculates headline earnings in accordance with the latest SAICA Circular ’Headline Earnings’. NHEPS is calculated by
starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal
operations as follows:
❚ 	Once-off transactions, for example restructuring costs, initial costs related to the Prudential book transfer, transaction costs
related to interest rate derivatives and initial deferred tax assets raised on previously unrecognised assessed losses;
❚ 	Unusual items – Discovery considers items to be unusual when they have limited predictive value and it is reasonable that items
of similar nature would not necessarily arise for several future annual reporting periods. These adjustments include those gains
or losses impacting profit or loss associated with changes in economic assumptions recognised in profit or loss, net of any gains
or losses on derivatives to offset such changes in economic assumptions; or
❚ 	Income or expenses not considered to be part of Discovery’s normal operations, for example amortisation of intangibles from
business combinations and fair value gains or losses on certain foreign exchange contracts not designated as hedges.
Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the
policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for transparency and consistency.

-- 32 of 50 --

34 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2021
ACCOUNTING POLICIES continued
BASIS OF PREPARATION
The Group's summary consolidated financial statements are prepared in accordance with the requirements of the JSE Limited
Listings and Debt Listings Requirements, and the requirements of the Companies Act of South Africa applicable to summary financial
statements. The Listings Requirements require summarised reports to be prepared in accordance with the framework concepts and
the measurement and recognition requirements of International Financial Reporting Standards (IFRS) and the SAICA Financial
Reporting Guides as issued by the Accounting Practices Committee and Financial Pronouncements as issued by the Financial
Reporting Standards Council and to also, as a minimum, contain the information required by IAS 34 Interim Financial Reporting.
The accounting policies applied in the preparation of the consolidated financial statements from which the summary consolidated
financial statements were derived are in terms of IFRS and are consistent with those accounting policies applied in the preparation
of the previous consolidated annual financial statements, except for the new accounting standards as set out earlier in this report.
AUDIT
The summary consolidated financial statements are extracted from audited information, but are not audited. The annual financial
statements were audited by PricewaterhouseCoopers Inc., who expressed an unmodified opinion thereon.
The audited annual financial statements and the auditor’s report thereon are available for inspection at the Company’s registered
office, together with the financial statements identified in the respective auditor’s reports.
The directors of Discovery take full responsibility for the preparation of this report and that the financial information has been
correctly extracted from the underlying annual financial statements.

-- 33 of 50 --

35
EMBEDDED VALUE STATEMENT
for the year ended 30 June 2021
The embedded value of Discovery consists of the following components:
❚ 	the adjusted net worth attributed to the business at the valuation date;
❚ 	plus: the present value of expected future shareholder cash flows from the in-force covered business; and
❚ 	less: the cost of required capital.
The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future
after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities,
whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the
new business written by Discovery, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses
and cost of required capital. The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Limited Group.
Covered business includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery
Health (“Health”) and Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality
Group, Ping An Health, AIA Health, Discovery Insure, Discovery Bank, VitalityInvest and Umbrella Funds, no published value has been
placed on the current in-force business as the businesses have not yet reached suitable scale with predictable experience.
In August 2011, Discovery raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference
shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth.
The 30 June 2021 embedded value results and disclosures were subjected to an external review.

-- 34 of 50 --

36 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2021
TABLE 1: GROUP EMBEDDED VALUE
R million
30 JUNE
2021
30 June
2020
%
change
Shareholders’ funds 	46 419 	44 553 	4
Adjustment to shareholders’ funds from published basis1 	(34 184) 	(32 080)
Adjusted net worth2 	12 235 	12 473
Value of in-force covered business before cost of required capital 	67 175 	64 305
Cost of required capital 	(4 765) 	(5 944)
Discovery Limited embedded value 	74 645 	70 834 	5
Number of shares (millions) 	656.8 	656.6
Embedded value per share 	R113.65 	R107.88 	5
Diluted number of shares (millions) 	665.1 	657.6
Diluted embedded value per share3 	R112.23 	R107.71 	4
1 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted
using the closing exchange rate of R19.74/GBP (June 2020: R21.44/GBP).
R million
30 JUNE
2021
30 June
2020
Life net assets under insurance contracts 	(20 675) 	(18 564)
Vitality Life Limited and Discovery funded VitalityLife business on the Prudential licence net assets under
insurance contracts 	(7 703) 	(6 320)
VitalityHealth financial reinsurance asset 	(2 353) 	(3 078)
VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax) 	(407) 	(467)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) 	(12) 	(21)
Goodwill relating to the acquisition of Standard Life Healthcare and the Prudential joint venture 	(2 442) 	(2 653)
Intangible assets (net of deferred tax) in covered businesses 	(830) 	(945)
Net preference share capital 	(779) 	(779)
Reversal of 1 Discovery Place IAS 17 financial lease accounting 	975 	747
Equity settled share based payment provision adjustment 	42 	–
(34 184) 	(32 080)
The ‘equity settled share based payment provision adjustment’ reflects the difference between the provision in the IFRS equity and the mark-to-
market value of the equity settled share based payments.
2 	The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the
embedded value:

-- 35 of 50 --

37
R million
30 JUNE
2021
30 June
2020
Shareholders’ funds 	46 419 	44 553
Adjustment to shareholders' funds 	(34 184) 	(32 080)
Adjusted net worth 	12 235 	12 473
Excess of available capital over adjusted net worth 	30 718 	23 231
Available capital 	42 953 	35 704
Required capital 	32 699 	29 932
Excess available capital 	10 254 	5 772
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth and the available
capital. This includes:
◼ The net preference share capital of R779 million which is included as available capital.
◼ The difference between Vitality Life Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth and adds back the negative
reserves eliminated on the Discovery funded VitalityLife business on the Prudential licence.
◼ The difference between Life’s Pillar 1 Own Funds and its adjusted net worth.
The following table sets out the required capital for each of the covered businesses:
R million
30 JUNE
2021
30 June
2020
Health and Vitality 	973 	935
Life and Invest 	22 059 	18 544
VitalityHealth 	2 847 	2 963
VitalityLife 	6 820 	7 490
Total Required Capital 	32 699 	29 932
◼ For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost.
◼ For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
◼ For VitalityHealth, the required capital amount was set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement.
◼ For the VitalityLife business on the Prudential licence, the required capital was set equal to the UK Solvency I long-term insurance
capital requirement as per the agreement with Prudential up to the Part VII transfer, thereafter it is set equal to 1.5 times the
Solvency II Pillar 1 Solvency Capital Requirement. For the business sold on the Vitality Life Limited licence, the required capital was
set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement up to the Part VII transfer and 1.5 times thereafter.
3 The diluted embedded value per share adjusts for treasury shares held in the Discovery BEE Share Trust and as part of Discovery’s
Long-term Incentive Plan where the impact is dilutive.

-- 36 of 50 --

38 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2021
TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS
R million
VALUE
BEFORE
COST OF
REQUIRED
CAPITAL
COST OF
REQUIRED
CAPITAL
VALUE
AFTER
COST OF
REQUIRED
CAPITAL
at 30 June 2021
Health and Vitality 	22 503 	(422) 	22 081
Life and Invest1 	27 777 	(1 183) 	26 594
VitalityHealth2 	8 230 	(462) 	7 768
VitalityLife2 	8 665 	(2 698) 	5 967
Total 	67 175 	(4 765) 	62 410
at 30 June 2020
Health and Vitality 	22 321 	(419) 	21 902
Life and Invest1 	23 752 	(1 244) 	22 508
VitalityHealth2 	10 077 	(495) 	9 582
VitalityLife2 	8 155 	(3 786) 	4 369
Total 	64 305 	(5 944) 	58 361
1 Included in the Life and Invest value of in-force covered business is R1 675 million (June 2020: R1 440 million) in respect of investment management
services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R19.74/GBP (June 2020: R21.44/GBP).
TABLE 3: GROUP EMBEDDED VALUE EARNINGS
R million
30 JUNE
2021
30 June
2020
Embedded value at end of period 	74 645 	70 834
Less: embedded value at beginning of period 	(70 834) 	(71 217)
Increase in embedded value 	3 811 	(383)
Net change in capital1 	(914) 	–
Dividends paid 	63 	1 494
Transfer to hedging reserve 	(260) 	430
Employee share option schemes 	(330) 	(164)
Increase in treasury shares 	907 	4
Acquisition of subsidiaries with non-controlling interest 	– 	(6)
IFRS transitional arrangements2 	– 	41
Embedded value earnings 	3 277 	1 416
Annualised return on opening embedded value 	4.6% 	2.0%
1 The net change in capital reflects share issues (net of costs) and an increase (decrease) in treasury shares in the period.
2 The IFRS transitional arrangements reflects the retrospective adjustments arising from the adoption of IFRS 9 and IFRS 15 to the opening balances
at 1 July 2018.

-- 37 of 50 --

39
TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS
YEAR
ENDED
30 JUNE
2021
Year ended
30 June
2020
R million
Net
worth
Cost of
required
capital
Value of
in-force
covered
business
EMBEDDED
VALUE
Embedded
value
Total profit from new business (at point of sale) 	(4 540) 	(262) 	6 693 	1 891 	1 922
Profit from existing business
◼ Expected return 	4 958 	107 	1 356 	6 421 	6 388
◼ Change in methodology and assumptions1 	1 006 	1 176 	(7 738) 	(5 556) 	(8 759)
◼ Experience variances 	1 081 	(143) 	3 979 	4 917 	133
Impairment, amortisation and fair value adjustment2 	(14) 	– 	– 	(14) 	(16)
Increase in goodwill and intangibles 	(336) 	– 	– 	(336) 	(313)
Other initiative costs3,5 	(324) 	– 	36 	(288) 	(781)
Non-recurring expenses 	(85) 	– 	– 	(85) 	(181)
Acquisition costs 4 	(41) 	– 	1 	(40) 	(12)
Finance costs 5,6 	(2 104) 	– 	– 	(2 104) 	(1 946)
Foreign exchange rate movements6 	(1 160) 	301 	(1 457) 	(2 316) 	3 922
Other7 	(8) 	– 	– 	(8) 	19
Return on shareholders’ funds5,8 	795 	– 	– 	795 	1 040
Embedded value earnings 	(772) 	1 179 	2 870 	3 277 	1 416
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to
the operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to
previous embedded value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, the PrimeMed acquisition and capital expenditure in
VitalityInvest and Discovery Group Europe Limited.
3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health) and costs of start-up
businesses (including Discovery Bank, VitalityInvest, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest). Head
office costs which relate to non-covered business are also included in this item.
4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has
been written over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value
or the value of new business and therefore the costs are not deducted from the value of new business.
5 Finance costs are aligned to the segmental earnings view of finance costs, before IFRS reporting adjustments. From 30 June 2021, the segmental
view of finance costs is shown gross of finance costs relating to intercompany loans between entities within the Group (R824 million for the twelve
months ended 30 June 2021 and R720 million for the twelve months ended 30 June 2020). Similar offsetting adjustments, which had previously
been included as investment return components in other initiative costs and return on shareholders’ funds, have been reallocated and are now
entirely included in the return on shareholders’ funds. The prior period comparatives have been restated to reflect this reallocation.
6 From 30 June 2021, foreign exchange gains / (losses) emerging through the income statement have been reallocated out of finance costs and into
foreign exchange rate movements. The prior period comparatives have been restated to reflect this reallocation.
7 This item includes, among other items, the tax benefits or losses that will emerge as the VitalityHealth DAC and intangible software assets amortise
or increase.
8 The return on shareholders’ funds is shown net of tax and management charges.

-- 38 of 50 --

40 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2021
TABLE 5: EXPERIENCE VARIANCES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	TOTAL
Renewal expenses 	229 	– 	(10) 	2 	(4) 	– 	17 	– 	234
Lapses and surrenders1 	23 	130 	(29) 	1 029 	– 	160 	(100) 	491 	1 704
Mortality and morbidity2 	– 	– 	(681) 	87 	938 	– 	108 	– 	452
Policy alterations1 	– 	9 	(438) 	420 	– 	– 	21 	10 	22
Premium and fee income1 	66 	– 	(47) 	(71) 	89 	– 	5 	18 	60
Economic 3 	33 	579 	69 	870 	– 	– 	– 	– 	1 551
Commission 	– 	– 	– 	– 	21 	– 	– 	– 	21
Tax 4 	75 	– 	339 	(352) 	65 	– 	(8) 	– 	119
Reinsurance 	– 	– 	– 	– 	(4) 	– 	(102) 	(67) 	(173)
Maintain modelling term5 	– 	362 	– 	188 	– 	79 	– 	– 	629
Vitality benefits 	(8) 	– 	– 	– 	– 	– 	41 	– 	33
Other6 	2 	– 	(136) 	100 	152 	– 	355 	(208) 	265
Total 	420 	1 080 	(933) 	2 273 	1 257 	239 	337 	244 	4 917
1 For Life and Invest, the combined lapse and surrender experience, policy alterations experience and premium and fee income experience is relative
to assumptions which include an allowance for a short-term stress set at 30 June 2020 in response to deteriorating experience from COVID-19
related impacts. For VitalityLife, the lapse and surrender experience is relative to assumptions which include the allowance for a short-term stress
for lapses introduced at 30 June 2020.
2 The mortality and morbidity experience for Life and Invest reflects claims in excess of the COVID-19 claims provision set at 30 June 2020. The
mortality and morbidity experience for VitalityHealth relates to experience emerging after the inclusion of a short-term premium deferral provision
for treatments delayed due to ongoing national lockdowns from the pandemic.
3 For Health and Vitality, the economic experience variance relates to the impact on administration and managed care fees of in-period inflation
being higher than that assumed. The experience for Life and Invest arises largely due to higher than expected linked asset growth for the period
under review.
4 The tax variance for Life and Invest arises due to the timing difference between the expected tax payments and actual payments.
5 For Health and Vitality, Life and Invest and VitalityHealth, the projection term is rebased at each year-end. Therefore, an experience variance arises
because the total term of the in-force covered business is effectively increased by twelve months.
6 The key Other experience relates to cash flow timing variances in Life and Invest, profits and losses from companies within the VitalityHealth and
VitalityLife segments which are not part of covered business, and movements in the value of the swaption in VitalityLife.

-- 39 of 50 --

41
TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	TOTAL
Modelling changes1 	– 	44 	(38) 	207 	– 	(64) 	2 	138 	289
Expenses 	– 	(597) 	(34) 	(273) 	– 	– 	36 	100 	(768)
Lapses2 	– 	– 	(6) 	(4) 	– 	– 	(622) 	(1 811) 	(2 443)
Mortality and morbidity3 	– 	– 	– 	(1 439) 	– 	(604) 	(151) 	2 171 	(23)
Benefit changes 	– 	16 	– 	– 	– 	– 	– 	– 	16
Tax 4 	– 	– 	– 	– 	– 	(469) 	– 	(235) 	(704)
Economic assumptions5 	– 	(2 004) 	(21) 	395 	– 	(240) 	(269) 	487 	(1 652)
Premium and fee income 	– 	(45) 	– 	(131) 	– 	– 	– 	– 	(176)
Reinsurance and financing6 	– 	– 	2 107 	(2 125) 	– 	(25) 	– 	41 	(2)
Other 	– 	– 	2 	(95) 	– 	– 	– 	– 	(93)
Total 	– 	(2 586) 	2 010 	(3 465) 	– 	(1 402) 	(1 004) 	891 	(5 556)
1 For Life and Invest, a correction was made to the calculation of the overall tax adjustment to the value of in-force. In addition, the Group Life
business’s expense allocation was revised and the projection term was extended from ten to twenty years. For VitalityHealth, the modelling changes
relate to a correction to the premium recorded against certain lapsed policies. For VitalityLife, the modelling changes include a reduction of the
premium increases on index-linked policies as per product specifications under current low inflation rates and several other minor refinements to
the calculation of the value of in-force and cost of capital.
2 For VitalityLife, the lapse assumption change relates to a reduction in the lapse rates for the whole of life business.
3 For Life and Invest, the mortality and morbidity assumption change relates to the COVID-19 provision raised in respect of an expected third and
fourth wave in South Africa. For VitalityLife, the change relates to a review of the mortality basis for the whole of life business. For VitalityHealth,
the change relates to a short-term stressed provision established for COVID-19 related impacts.
4 For VitalityHealth and VitalityLife, the tax assumption change relates to an increase in the UK corporation tax rate from 19% to 25% from April 2023.
5 For Life and Invest and Health and Vitality, the economic assumptions item relates to the impact of updating the assumptions relative to the
Johannesburg Limited (“JSE”) nominal and real yield risk-free curves at 30 June 2021. For Life and Invest this also includes the impact of updating
exchange rate assumptions. For VitalityLife the item includes the impact of updating the assumptions relative to the Solvency II yield curves and
the IFRS interest rates, offset by the net change in the interest rate hedge.
6 For Life and Invest, the reinsurance and financing item primarily relates to the impact of financing arrangements.

-- 40 of 50 --

42 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2021
TABLE 7: EMBEDDED VALUE OF NEW BUSINESS
R million
30 JUNE
2021
30 June
2020
Health and Vitality
Present value of future profits from new business (at point of sale) 	789 	910
Cost of required capital 	(24) 	(27)
Present value of future profits from new business (at point of sale) after cost
of required capital 	765 	883 	(13)
New business annualised premium income1 	3 704 	3 972 	(7)
Life and Invest
Present value of future profits from new business (at point of sale)2 	825 	668
Cost of required capital 	(82) 	(82)
Present value of future profits from new business (at point of sale) after cost
of required capital 	743 	586 	27
New business annualised premium income3 	2 947 	2 886 	2
Annualised profit margin4 	3.0% 	2.5%
Annualised profit margin excluding Invest business 	5.7% 	5.8%
VitalityHealth5
Present value of future profits from new business (at point of sale) 	143 	262
Cost of required capital 	(61) 	(56)
Present value of future profits from new business (at point of sale) after cost
of required capital 	82 	206 	(60)
New business annualised premium income6 	1 263 	1 308 	(3)
Annualised profit margin4 	0.9% 	2.5%
VitalityLife7
Present value of future profits from new business (at point of sale) 	396 	353
Cost of required capital 	(95) 	(106)
Present value of future profits from new business (at point of sale) after cost
of required capital 	301 	247 	22
New business annualised premium income 	871 	956 	(9)
Annualised profit margin4 	4.1% 	3.2%

-- 41 of 50 --

43
1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income
shown above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as
well as premiums in respect of new business written during the period but only activated after 30 June 2021.
The total Health and Vitality new business annualised premium income written over the period was R6 103 million (June 2020: R6 236 million).
2 Included in the Life and Invest embedded value of new business is R53 million (June 2020: R29 million) in respect of investment management
services provided on off balance sheet investment business.
Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which
has been recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first
premium is due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has
not been refunded after receipt. Invest new business also includes Discovery Retirement Optimiser policies to which Life and Invest became
contractually bound during the reporting period, including policies whose first premium is due after the valuation date.
The new business annualised premium income of R2 947 million (June 2020: R2 886 million) (single premium APE: R1 490 million (June 2020:
R1 453 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total new
business annualised premium income written over the period, including automatic premium increases of R1 414 million (June 2020: R1 496 million)
and servicing increases of R640 million (June 2020: R576 million), was R5 001 million (June 2020: R4 958 million) (single premium APE: R1 569 million
(June 2020: R1 507 million)). Single premium business is included at 10% of the value of the single premium.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans, are shown in Table 5
as experience variances and not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation
date multiplied by the Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The
assumptions for the Margin and Annuity Factor are shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised
premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first
month, as well as premiums in respect of new business written during the period but only activated after 30 June 2021.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies
whose first premium is due after the valuation date.

-- 42 of 50 --

44 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2021
BASIS OF PREPARATION
TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS
30 JUNE
2021
30 June
2020
Beta coefficient 	0.75 	0.75
Equity risk premium (%) 	3.5 	3.5
Risk discount rate (%)
– Health and Vitality1 	13.125 	14.125
– Life and Invest1 	13.625 	15.125
– VitalityHealth 	3.46 	2.89
– VitalityLife 	3.263 	3.065
Rand / GBP exchange rate
Closing 	19.74 	21.44
Average 	20.74 	19.75
Margin over Expense inflation to derive Medical inflation (%)
South Africa 	3.00 	3.00
Expense inflation (%)2
South Africa 	– Health and Vitality 	6.14 	7.39
– Life and Invest 	6.23 	8.33
United Kingdom 	2.50 	2.50
Pre-tax investment return (%)
South Africa 	– Cash1 	9.50 	11.00
– Life and Invest bonds3 	11.00 	12.50
– Health and Vitality bonds3 	10.50 	11.50
– Equity1 	14.50 	16.00
United Kingdom – VitalityHealth risk-free rate 	0.84 	0.27
– VitalityLife risk-free rate 	0.64 	0.44
– VitalityLife IFRS interest rate 	1.80 	1.35
– VitalityLife investment return 	1.44 	1.58
Corporation tax rate (%)
South Africa 	28 	28
United Kingdom – long-term 	25 	19
VitalityHealth Assumptions
– Margin (net of tax and cost of capital) (%) 	12.0 	13.7
– Annuity Factor 	6.18 	6.37
Projection term
– Health and Vitality 	20 years 	20 years
– Discovery Life – VIF 	40 years 	40 years
– Group Life 	20 years 	10 years
– VitalityLife 	No cap 	No cap
– VitalityHealth4 	20 years 	20 years
1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow
weighted average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the Bank of England
inflation target.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.

-- 43 of 50 --

45
The Discovery Limited embedded value is calculated based on a risk discount rate using the CAPM approach with specific reference
to the Discovery beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount rate proxies the
result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed beta
calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta
will only change if the capital structure of the Group and / or the observed beta calculated using daily returns over a long time period
suggest the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect the
historic performance of share prices relative to the market they may not allow fully for non-market related and non-financial risk.
Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available,
augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery
Limited group information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding
expenses of an exceptional or non-recurring nature.
From 30 June 2020, the yield curves underlying the embedded value calculations were changed from the Prudential Authority yield
curves to the JSE yield curves. The South African investment return assumptions for Life, Invest, Health and Vitality were based on
the publically available JSE risk-free nominal yield curve. The real yield assumption was set based on the publically available JSE risk-
free real yield curve, adjusted to remove volatility due to the nature of the index-linked government bond market. Other economic
assumptions were set relative to these two yield curves.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining
the net investment return assumption.
The risk-free rate assumption for VitalityHealth and VitalityLife was based on the single interest rate derived from the Prudential
Regulatory Authority yield curve. The inflation rate is consistent with the Bank of England inflation target.
From 30 June 2018, VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by
the Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed
future lapse rates and premium increases. The Margin assumption reflects profit margins after tax and Cost of Capital. The
assumptions underlying the Annuity Factor and Margin are set taking into account the current experience in the business at different
durations.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on
tangible assets. The Vitality Life Limited and the VitalityLife business on the Prudential licence required capital amount is assumed
to earn the investment return assumption, which is set based on the return on a portfolio of government and corporate bonds
assumed to back the required capital. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is
limited to the cash flow available after having met both the required capital amount and an internally defined liquidity target capital
requirement of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”)
107: Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to
take into account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2.

-- 44 of 50 --

46 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021 	47
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2021
SENSITIVITY TO THE EMBEDDED VALUE ASSUMPTIONS
The risk discount rate uses the CAPM approach with specific reference to the Discovery beta coefficient. As beta values reflect the
historic performance of share prices relative to the market they may not allow fully for non-market related and non-financial risk.
Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The
sensitivity of the embedded value and the embedded value of new business at 30 June 2021 to changes in the risk discount rate is
included in the tables below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management
action such as risk premium increases where future experience is worse than the base assumptions.
TABLE 9: EMBEDDED VALUE SENSITIVITY
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
EMBEDDED
VALUE
%
change	R million
Adjusted
net worth 2
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Base 	12 235 	22 503 	(422) 	27 777 	(1 183) 	8 230 	(462) 	8 665 	(2 698) 	74 645
Impact of:
Risk discount rate +1% 	12 235 	21 254 	(458) 	25 145 	(1 258) 	7 789 	(438) 	8 323 	(3 489) 	69 103 	(7)
Risk discount rate – 1% 	12 235 	23 884 	(382) 	30 885 	(1 094) 	8 717 	(488) 	9 049 	(1 608) 	81 198 	9
Lapses – 10% 	11 962 	23 236 	(443) 	30 289 	(1 241) 	9 338 	(520) 	9 413 	(3 003) 	79 031 	6
Interest rates – 1%1 	10 969 	22 431 	(406) 	28 003 	(1 168) 	8 641 	(488) 	6 774 	(2 658) 	72 098 	(3)
Equity and property market value – 10% 	12 197 	22 503 	(422) 	27 236 	(1 201) 	8 230 	(462) 	8 665 	(2 698) 	74 048 	(1)
Equity and property return +1% 	12 235 	22 503 	(422) 	28 155 	(1 186) 	8 230 	(462) 	8 665 	(2 698) 	75 020 	1
Renewal expenses – 10% 	12 302 	24 722 	(390) 	28 346 	(1 156) 	8 868 	(462) 	8 825 	(2 663) 	78 392 	5
Mortality and morbidity – 5% 	12 446 	22 503 	(422) 	29 741 	(1 062) 	9 584 	(462) 	8 943 	(2 682) 	78 589 	5
Projection term +1 year 	12 235 	22 768 	(426) 	27 864 	(1 187) 	8 290 	(465) 	8 665 	(2 698) 	75 046 	1
1 All economic assumptions were reduced by 1%.
2 The sensitivity impact on the VitalityLife net of tax change in negative reserves is included in the adjusted net worth column.
The following table shows the effect of using different assumptions on the embedded value of new business.
TABLE 10: VALUE OF NEW BUSINESS SENSITIVITY
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
VALUE OF
NEW
BUSINESS
%
change	R million
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Base 	789 	(24) 	825 	(82) 	143 	(61) 	396 	(95) 	1 891
Impact of:
Risk discount rate +1% 	723 	(26) 	620 	(88) 	67 	(57) 	311 	(101) 	1 449 	(23)
Risk discount rate – 1% 	861 	(22) 	1 064 	(76) 	227 	(65) 	492 	(80) 	2 401 	27
Lapses – 10% 	839 	(26) 	1 035 	(86) 	252 	(67) 	545 	(122) 	2 370 	25
Interest rates – 1%1 	796 	(23) 	838 	(81) 	217 	(65) 	156 	(88) 	1 750 	(7)
Equity and property return +1% 	789 	(24) 	856 	(83) 	143 	(61) 	396 	(95) 	1 921 	2
Renewal expense – 10% 	908 	(22) 	874 	(81) 	220 	(61) 	427 	(93) 	2 172 	15
Mortality and morbidity – 5% 	789 	(24) 	924 	(74) 	307 	(61) 	431 	(90) 	2 202 	16
Projection term +1 year 	803 	(24) 	831 	(83) 	152 	(61) 	396 	(95) 	1 919 	1
Acquisition costs – 10% 	817 	(24) 	954 	(82) 	181 	(61) 	519 	(95) 	2 209 	17
1 All economic assumptions were reduced by 1%.

-- 45 of 50 --

48 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021
APPENDIX A
NEW BUSINESS ANNUALISED PREMIUM INCOME
The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations
of the Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance,
Discovery Health Medical Scheme’s (DHMS) new business is attributable to the medical scheme but is under the administration and
marketing of Discovery Health which earns a fee in respect of such services.
Core new business API increased by 9% for the year ended 30 June 2021 when compared to the same period in the prior year.
R million
JUNE
2021
June
2020
%
change
Discovery Health1 	6 079 	6 101 	–
Discovery Life 	2 264 	2 286 	(1)
Discovery Invest 	2 737 	2 667 	3
Discovery Insure 	1 287 	1 089 	18
Discovery Vitality 	24 	135 	(82)
VitalityHealth 	1 367 	1 238 	10
VitalityLife 	1 141 	1 257 	(9)
Ping An Health (25% interest) 	3 938 	3 575 	10
Other new businesses2 	2 114 	825 	156
Core new business API of Group 	20 951 	19 173 	9
New Closed Schemes1 	374 	– 	100
New business API of Group including new Closed Schemes 	21 325 	19 173 	11
Gross revenue Vitality Group3 	1 270 	1 134 	12
Total new business API and other new business 	22 595 	20 307 	11
1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes
and offerings such as GAP cover and Primary Care cover. The new business API for New Closed Schemes includes contracted new business API and
business in the first twelve months of on-boarding. Closed Schemes refer to those restricted to certain employers and industries.
2 Other new businesses include the Umbrella Fund, Discovery Insure commercial and VitalityInvest.
3 Vitality Group new business includes gross recurring and lump sum revenues earned by Vitality Group and specifically excludes revenue related
to cost recoveries and rewards.
Calculation of new business API
New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new
single premium policies. It also includes both automatic premium increases and servicing increases on existing long-term
insurance policies. The amounts exclude indirect taxes.
The new business API in the table above differs from the new business API disclosed in the embedded value largely as a result of:
– The timing of inclusion of policyholders in the calculation of new business API – In the embedded value, new business is included from
the earlier of the date that the first premium has been received or when the policy is on risk, whereas in the table above, new
business is included when the policy has been contractually committed.
– Inclusion of automatic premium increases and servicing increases on existing life policies – These are included in the table above but
excluded in the embedded value API values disclosed.
Refer to the Embedded value statement for the year ended 30 June 2021 in the footnotes to ‘Table 7: Embedded value of new business’
for a more detailed description of the differences in new business disclosures between the embedded value and the table above.

-- 46 of 50 --

49
GROSS INFLOWS UNDER MANAGEMENT
Gross inflows under management measures the total funds collected by Discovery. Gross inflows under management increased by
5% for the year ended 30 June 2021 when compared to the same period in the prior year.
R million
JUNE
2021
June
2020
%
change
Discovery Health 	90 651 	89 682 	1
Discovery Life 	13 714 	13 023 	5
Discovery Invest 	24 203 	24 501 	(1)
Discovery Insure 	4 107 	3 556 	15
Discovery Vitality 	2 295 	2 401 	(4)
VitalityHealth 	11 403 	9 651 	18
VitalityLife 	6 696 	5 917 	13
All other businesses 	8 974 	6 102 	47
Gross inflows under management 	162 043 	154 833 	5
Less: collected on behalf of third parties 	(88 827) 	(87 962) 	1
Discovery Health 	(81 849) 	(81 309) 	1
Discovery Invest 	(6 978) 	(6 653) 	5
Gross income of Group per the segmental information 	73 216 	66 871 	9
Gross income is made up as follows:
– Insurance premium revenue 	56 812 	50 517 	12
– Fee income from administration businesses 	11 711 	11 350 	3
– Vitality income 	3 340 	3 875 	(14)
– Other income 	1 353 	1 129 	20
Gross income of Group per the segmental information 	73 216 	66 871 	9

-- 47 of 50 --

50 DISCOVERY AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2021

-- 48 of 50 --

Transfer secretaries Computershare Investor Services Pty Limited
(Registration number: 2004/003647/07)
Rosebank Towers, 15 Biermann Avenue, Rosebank 2196
Private Bag X9000, Saxonwold, 2132
Sponsors and debt sponsors Rand Merchant Bank (A division of FirstRand Bank Limited)
Secretary and registered office NN Mbongo, Discovery Limited
(Incorporated in the Republic of South Africa)
(Registration number: 1999/007789/06)
Company tax reference number: 9652/003/71/7
JSE share code: 	DSY ISIN: ZAE000022331
JSE share code: 	DSBP ISIN: ZAE000158564
JSE bond company code: 	DSYI
1 Discovery Place, Sandton 2146 PO Box 786722, Sandton 2146
Tel: (011) 529 2888 Fax: (011) 539 8003
Directors ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive Officer), HL Bosman, Dr BA Brink, SE de Bruyn, R Farber,
M Hlahla3, HD Kallner*, F Khanyile, NS Koopowitz*, D Macready, Dr TV Maphai, HP Mayers1, Dr A Ntsaluba*, A Pollard*, B
Swartzberg*, M Schreuder2, DM Viljoen* (Financial Director), SV Zilwa
* Executive.
1 Retired effective 26 November 2020.
2 Appointed effective 19 February 2021.
3 Appointed effective 15 August 2021.
Debt officer DM Viljoen
Annual financial results
– supervised by DM Viljoen CA(SA)
Embedded value statement
– prepared by P Bolink FASSA
– supervised by A Rayner FASSA, FIA

-- 49 of 50 --

Discovery
+27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za
Subsidiaries of Discovery Limited are authorised financial services providers.

-- 50 of 50 --